<!DOCTYPE html><html dir=ltr lang=en><head><meta charset=utf-8><meta content="width=device-width, initial-scale=1, shrink-to-fit=no" name=viewport><meta content="New, high-quality SMLE questions for you" name=description><meta content="Obstetrics & Gynecology" property=og:title><meta content=article property=og:type><meta content=https://cdn.jsdelivr.net/emojione/assets/3.1/png/128/1f469-1f3fc-2695.png property=og:image><title>Obstetrics &amp; Gynecology</title><link crossorigin=anonymous href=https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/css/bootstrap.min.css integrity=sha384-PsH8R72JQ3SOdhVi3uxftmaW6Vc51MKb0q5P2rRUpPvrszuE4W1povHYgTpBfshb rel=stylesheet><link crossorigin=anonymous href=https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css integrity=sha384-wvfXpqpZZVQGK6TAh5PVlGOfQNHSoD2xbE+QkPxCAFlNEevoEH3Sl0sibVcOQVnN rel=stylesheet><link href="https://fonts.googleapis.com/css?family=Roboto:400,700|Spectral+SC:700" rel=stylesheet><link href=https://cdn.jsdelivr.net/emojione/assets/3.1/png/128/1f469-1f3fc-2695.png rel=icon><style>body{font-family:'Roboto',sans-serif}h1{font-family:'Spectral SC',serif;font-weight:700;font-size:3.5rem}h1,.subtitle{text-align:center}h1{overflow-y:hidden;overflow-x:auto}.question-container+.question-container{border-top:1px solid #ededed}.explanation-text{background-color:#ededed}.question-number{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none}#question-count,.question-number{color:#d21414}.subtitle{font-size:.8rem}.subtitle a{font-style:italic}.question-text{font-weight:bold;text-align:justify}ol li:hover{background-color:#ededed}@keyframes red-heart{0%{color:#d21414}75%{color:#d21414}100%{color:black}}.fa.fa-heart{color:#d21414;animation:red-heart 2s ease-in infinite alternate}#header-separator{text-align:center;color:#ededed}#header-separator:after{content:'\002665';display:inline-block;position:relative;top:-15px;padding:0 10px;background:white;color:#ededed;font-size:18px}</style></head> <body> <div class=container> <div class="row justify-content-center"> <div class="col col-md-8 col-lg-6"> <h1 class=mt-5>Obstetrics &amp; Gynecology</h1> <p class=subtitle><span id=question-count>117</span> new, high-quality questions for the <abbr title="Saudi Medical Licensing Exam">SMLE</abbr> <a href=index.html>(see all)</a></p> <hr id=header-separator> <div id=questions><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>1. </span> Which of the following is the most common cause of anemia in pregnancy? </p><ol class=mt-3 type=A><li>Vitamin K deficiency</li><li>Iron deficiency</li><li>Vitamin B12 deficiency</li><li>Folate deficiency</li></ol><button aria-controls=explanation-3NJ aria-expanded=false class="btn btn-secondary" data-target=#explanation-3NJ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-3NJ><p class=correct-answer><strong>Answer:</strong> B</p>1. With normal pregnancy, blood volume increases, which results in a concomitant hemodilution. <br>2. Although red blood cell (RBC) mass increases during pregnancy, plasma volume increases more, resulting in a relative anemia. This results in a physiologically lowered hemoglobin (Hb) level, hematocrit (Hct) value, and RBC count.<br><strong>3. Iron deficiency is the most common cause of anemia in pregnancy (75-95% of the cases of anemia in pregnant women)</strong><br>4. <span style="text-decoration: underline;"><strong>Clinical symptoms</strong></span> of iron deficiency anemia include fatigue, headache, restless legs syndrome, and pica (in extreme situations).<br>5. <span style="text-decoration: underline;"><strong>Treatment</strong></span> consists of additional supplementation with oral iron sulfate<br><br><span style="text-decoration: underline;"><strong>Hemoglobin levels change during pregnancy</strong></span><br>1. Wanes in second trimester due to hemodilution<br>2. Increases in third trimester<br>3. Falls with delivery with placental separation</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>2. </span> A 60-year-old woman presents to the physician with vaginal dryness, dyspareunia, dysuria and increased urinary frequency. Examination shows scarce pubic. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Lichen sclerosis</li><li>Urinary Tract Infection</li><li>Vaginal cancer</li><li>Atrophic vaginitis</li></ol><button aria-controls=explanation-ZWV aria-expanded=false class="btn btn-secondary" data-target=#explanation-ZWV data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ZWV><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Menopause</strong> is the result of permanent loss of estrogen. Menopause occurs in patients aged 48 to 52. <br>2. Symptoms of menopause include irregular or absent menses, heat intolerance, flushing, insomnia, dyspareunia and night sweats. <br>3. <strong>Vaginal atrophy</strong> (<strong>atrophic vaginitis</strong>) is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to loss of estrogen.<br>4. Vaginal atrophy presents with vaginal dryness and dysuria, and physical exam findings of pale, dry vaginal mucosa, diminished labial fat pad, and scarce pubic hair. <br><strong>5. It typically occurs in menopausal women.</strong><br>6. Atrophic vaginitis is treated with estrogen</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>3. </span> The most frequently reported symptom of vulvar cancer is which one of the following? </p><ol class=mt-3 type=A><li>Pain</li><li>Dysuria</li><li>Bleeding</li><li>Longstanding pruritus</li></ol><button aria-controls=explanation-WDJ aria-expanded=false class="btn btn-secondary" data-target=#explanation-WDJ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-WDJ><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Vulvar cancer </strong>is usually a squamous cell skin cancer, most often occurring in elderly women.<br>2. It usually manifests as a palpable lesion.<br>3. Most patients with vulvar cancer present with a palpable vulvar lesion, frequently noticed by the woman or by a clinician during pelvic examination. Women often have a long history of pruritus.<br>4. Average age at diagnosis is about 70, and incidence increases with age.<br>5. Diagnosis is by biopsy. <br>6. Treatment typically includes excision and lymph node dissection or sentinel lymph node mapping.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>4. </span> A 30-year-old gravida 3 para 2 presents with fever of 39 C, a pain in her flank and chills. On examinations, there is slight bilateral costovertebral angle tenderness.Lab results reveal positive urinalysis (presence of nitrites and white blood cells). Which of the following is the treatment of choice for this patient? </p><ol class=mt-3 type=A><li>nitrofurantoin</li><li>levofloxacin</li><li>trimethoprim/sulfamethoxazole</li><li>Intravenous ceftriaxone</li></ol><button aria-controls=explanation-ERO aria-expanded=false class="btn btn-secondary" data-target=#explanation-ERO data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ERO><p class=correct-answer><strong>Answer:</strong> D</p>Pyelonephritis<br>1. Patient presents with urinary frequency, urgency, burning, and dysuria in the<br>2. same way as cystitis, and there is flank pain and tenderness. Pyelonephritis<br>3. is also a more severe disease, so there is a higher fever and the patient is much<br>4. more ill.<br>5. Diagnostic: Urinalysis and urine culture the same as for cystitis<br>6. Treatment: Any of the medications for gram-negative bacilli are effective. Ciprofloxacin is recommended for outpatient treatment. <br>7. For inpatient therapy use ceftriaxone, ertapenem, quinolones, ampicillin, and gentamicin.<br>8.Sulfonamides are contraindicated late in pregnancy because they may increase the incidence of kernicterus. 9.Tetracyclines are contraindicated because administration late in pregnancy may lead to discoloration of the child’s deciduous teeth.<br>10.Nitrofurantion may induce hemolysis in women who are deficient in G6PD,</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>5. </span> Regarding external cephalic version (ECV) which of the following is contrainidcated? </p><ol class=mt-3 type=A><li>34 weeks' gestation</li><li>Maternal age of 35</li><li>Maternal hypertension</li><li>Polyhydramnios</li></ol><button aria-controls=explanation-IAC aria-expanded=false class="btn btn-secondary" data-target=#explanation-IAC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-IAC><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>External cephalic version</strong> (ECV) is a procedure that externally rotates the fetus from a breech presentation to a cephalic presentation.<br>2. External cephalic version can be attempted on fetuses that are detected before the onset of labor and <strong><span style="text-decoration: underline;">after 37 weeks' gestation.</span></strong><br>3. Version before 37 weeks is not recommended because of the risk that the fetus may revert to a breech presentation before delivery and the risk of delivery of a premature infant. <br>4. Successful version of a breech into cephalic presentation allows women to avoid cesarean delivery, which is currently the largest contributing factor to the incidence of postpartum maternal morbidity.<br>5. Contraindications to ECV exist either when the procedure may put the fetus in jeopardy or when the procedure is very unlikely to succeed. <br>6. Clearly, if cesarean delivery is indicated for reasons other than breech presentation, ECV is contraindicated.<br>7. Placenta previa or abruptio placentae, nonreassuring fetal status, intrauterine growth restriction in association with abnormal umbilical artery Doppler index, isoimmunization, severe preeclampsia, recent vaginal bleeding, and significant fetal or uterine anomalies are also contraindications for ECV.<br>8. Other contraindications to ECV include ruptured membranes, fetus with a hyperextended head, and multiple gestations, although ECV may be considered for a second twin after delivery of the first.<br>9. Relative contraindications include maternal obesity, small for gestational age fetus (less than 10%), and oligohydramnios because they make successful ECV less likely.<br>10.  Previous uterine scar from cesarean delivery or myomectomymay also be a relative contraindication for ECV.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>6. </span> Which of the following is true regarding endometriosis? </p><ol class=mt-3 type=A><li>Defined as menstrual bleeding with abnormal duration, quantity, or schedule.</li><li>Defined as prolonged or heavy menstruation, typically lasting longer than 7 days or exceeding 80 ml.</li><li>Defined as the presence of endometrial glands in the uterine muscle.</li><li>Defined as the presence of endometrial glands and stroma outside of the uterine cavity.</li></ol><button aria-controls=explanation-EZE aria-expanded=false class="btn btn-secondary" data-target=#explanation-EZE data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-EZE><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Endometriosis</strong></span> <br>1. Presence of endometrial tissue outside the uterus (e.g., ovaries, broad ligament); ectopic tissue follows same menstrual cycle as normal tissue <br>2. Retrograde menstruation, vascular/lymphatic spread of endometrial tissue from uterus to pelvic cavity, or iatrogenic spread of endometrial tissue (e.g., during caesarian section) are most plausible causes of condition. <br>3. Risk factors family history, infertility, nulliparity , low body mass index <br>4. Clinical features: dysmenorrhea, dyspareunia, painful bowel movements (dyschezia), pelvic pain, possible infertility; uterine or adnexal tenderness; palpable adhesions on uterus or ovaries<br><strong>5. Laparoscopy is the gold standard for the diagnosis of endometriosis. </strong><br>6. Oral contraceptive pills are first line agents in the treatment of endometriosis in young women desiring future fertility.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>7. </span> A 22­-year ­old female presents to the physician with amenorrhea, headache and galactorrhea. Her pregnancy test is negative, serum prolactin is &gt; 200 mg/dL. MRI showed a pituitary mass of 15 mm. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Craniopharyngioma</li><li>Prolactinoma</li><li>Astrocytomas</li><li>Kallmann syndrome</li></ol><button aria-controls=explanation-V31 aria-expanded=false class="btn btn-secondary" data-target=#explanation-V31 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-V31><p class=correct-answer><strong>Answer:</strong> B</p><span style="text-decoration: underline;"><strong>Prolactinoma<br></strong></span><br>1. Prolactin­ secreting tumor is the most common cause in adolescents <br><strong>2. Prolactinomas are the most common hormone-secreting pituitary tumors.</strong><br>3. Based on its size, a prolactinoma can be classified as a microprolactinoma (&lt; 10 mm diameter) or a macroprolactinoma (&gt;10 mm diameter).<br>4. Patients with microprolactinoma generally have an excellent prognosis. <br>5. Macroprolactinomas have a tendency to grow with time and require aggressive treatment to prevent complications.<br>6. <span style="text-decoration: underline;"><strong>Clinical presentation</strong></span>: Headache, amenorrhea, galactorrhea and visual disturbance if tumor affect the optic chiasm, e.g. bitemporal hemianopsia or total vision loss in severe cases.  <br><span style="text-decoration: underline;"><strong><br>Diagnosis</strong></span> <br> 1. Elevated serum PRL (prolactin) <br> 2. TSH and pregnancy test must be performed<br> 3. MRI: A serum PRL value of 200 ng/mL or greater in the presence of a macroadenoma (&gt; 10 mm) is virtually diagnostic of prolactinoma. <br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span><br>1. Bromocriptine <br>2. Cabergoline. Better tolerated than bromocriptine.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>8. </span> Which of the following is the most common cause of hereditary breast and ovarian cancers? </p><ol class=mt-3 type=A><li>BRCA mutation</li><li>CDH1</li><li>p53 mutation</li><li>Alpha-fetoprotein</li></ol><button aria-controls=explanation-H2E aria-expanded=false class="btn btn-secondary" data-target=#explanation-H2E data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-H2E><p class=correct-answer><strong>Answer:</strong> A</p><strong>BRCA1 and BRCA2 mutations are the most common cause of hereditary breast and ovarian cancers. </strong><br>Patients with BRCA1 or BRCA2 gene mutations should be followed very closely to look for breast or ovarian cancer and may want to consider prophylactic mastectomies and oophorectomies. <br><strong>Risk factors for ovarian cancer</strong>: family history, infertility, nulliparity, BRCA1 or BRCA2 gene mutations  <br><br><strong>Risk factors for breast cancer: </strong><br>1. Female gender, older age.<br>2. Breast cancer in a first-degree relative.<br>3. BRCA1 and BRCA2 mutations (associated with early onset).<br>4. A personal history of breast cancer.<br>5. A high-fat and low-fiber diet.<br>6. A history of fibrocystic change with cellular atypia.<br>7. Exposure to estrogen (nulliparity, early menarche, late menopause).<br>8. First full-term pregnancy after age 35.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>9. </span> Which of the following is the most common cause of mastitis? </p><ol class=mt-3 type=A><li>Staphylococcus pyogenes</li><li>Staphylococcus mutans</li><li>Staphylococcus aureus</li><li>Viridans streptococci</li></ol><button aria-controls=explanation-5UE aria-expanded=false class="btn btn-secondary" data-target=#explanation-5UE data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-5UE><p class=correct-answer><strong>Answer:</strong> C</p>1.<span style="text-decoration: underline;"><strong> Lactational mastitis</strong></span> is a localized, painful inflammation of the breast associated with fever and malaise that occurs in breastfeeding women.<br>2. <span style="text-decoration: underline;"><strong>Risk factors</strong></span> for lactational mastitis include an episode of mastitis with a previous child, severe prolonged unilateral engorgement, poor milk drainage and nipple excoriation or cracking.<br>3. <span style="text-decoration: underline;"><strong>Presents</strong></span> as a hard, red, tender, swollen area of one breast associated with fever &gt;38.3º C in a nursing mother.<br>4. Other systemic complaints may variably include myalgia, chills, malaise, and flu-like symptoms. In the early stages of breast infection the presentation can be subtle with few clinical signs, while patients with advanced infection may present with a large area of breast swelling with overlying skin changes (eg, erythema).<br><strong>5. It is mostly caused by Staphylococcus aureus.</strong><br>6. The diagnosis of mastitis is made clinically. <br><strong>7. Breastfeeding is not contraindicated in mastitis.</strong><br>8. <span style="text-decoration: underline;"><strong>Treatment</strong></span>: PO antibiotics (e.g., penicillin, dicloxacillin, erythromycin) and Incision and drainage of breast abscess if present.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>10. </span> A 21-year old lactating mother comes to the doctor with left breast pain that started few days ago. The pain is associated with fever and fatigue. Examination shows tenderness, and swelling of the left breast. <br>Which of the following is the appropriate management of this patient? </p><ol class=mt-3 type=A><li>Stop breastfeeding</li><li>Incision and drainage</li><li>Analgesics, frequent breastfeeding and antibiotics</li><li>Needle biopsy</li></ol><button aria-controls=explanation-6OY aria-expanded=false class="btn btn-secondary" data-target=#explanation-6OY data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-6OY><p class=correct-answer><strong>Answer:</strong> C</p><span style="text-decoration: underline;"><strong>Mastitis</strong></span> <br>1. Lactational mastitis: Common in the first few months of lactation.<br>2. It is mostly caused by Staphylococcus aureus, affects one quadrant and is treated with penicillinase resistant penicillin. <br><strong>3. Mastitis is not a contraindication to breastfeeding.</strong><br>4. Symptoms often begin 2–4 weeks postpartum; are usually unilateral; and include focal breast tenderness, erythema, edema, warmth, and possible purulent nipple drainage.<br>5. <strong>Treatment</strong>: Continued breast-feeding and PO antibiotics (e.g., penicillin, dicloxacillin, erythromycin).<br>6. Incision and drainage of breast abscess if present.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>11. </span> What is the normal amount of blood loss during vaginal delivery? </p><ol class=mt-3 type=A><li>1500 mL</li><li>1000 mL</li><li>500 mL</li><li>2000 mL</li></ol><button aria-controls=explanation-CC4 aria-expanded=false class="btn btn-secondary" data-target=#explanation-CC4 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-CC4><p class=correct-answer><strong>Answer:</strong> C</p>The average amount of blood loss after the birth of a single baby in vaginal delivery is about 500 ml (or about a half of a quart). The average amount of blood loss for a cesarean birth is approximately 1,000 ml (or one quart). Most postpartum hemorrhage occurs right after delivery, but it can occur later as well.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>12. </span> Which of the following medications is considered safe during pregnancy? </p><ol class=mt-3 type=A><li>Valproic acid</li><li>Methyldopa</li><li>Lisinopril</li><li>Tetracyclines</li></ol><button aria-controls=explanation-V2T aria-expanded=false class="btn btn-secondary" data-target=#explanation-V2T data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-V2T><p class=correct-answer><strong>Answer:</strong> B</p><strong>Tetracyclines</strong> may cause permanent yellow-gray-brown discoloration of the teeth and enamel hypoplasia. The use of tetracycline during pregnancy is generally not recommended, especially during the last half of pregnancy.<br><br><strong>Angiotensin-converting-enzyme inhibitor</strong> (e.g enalapril , lisinopril) are contraindicated in pregnancy as they can cause renal failure ,fetal growth restriction, oligohydramnios, pulmonary hypoplasia,and skeletal abnormalities if administered in the second or third trimester. <br><br><strong>Valproic acid and carbamazepine</strong> can cause Neural tube defects <br><br><strong>Methyldopa</strong> is a drug of first choice for control of mild to moderate hypertension in pregnancy.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>13. </span> Which of the following medications is used to prevent the transmission of Group B streptococcus (GBS) to the infant during labor? </p><ol class=mt-3 type=A><li>Sulfadiazine</li><li>Penicillin</li><li>Pyrimethamine</li><li>Azithromycin</li></ol><button aria-controls=explanation-X8R aria-expanded=false class="btn btn-secondary" data-target=#explanation-X8R data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-X8R><p class=correct-answer><strong>Answer:</strong> B</p>1. <strong>Bacterial infections</strong> can affect pregnant women from implantation of the fertilized ovum through the time of delivery and peripartum period. They may also affect the fetus and newborn. <br>2. <strong>Group B Streptococcus</strong> (GBS; Streptococcus agalactiae) is the most common cause of life-threatening infections in newborns and can also affect the mother.<br><br><span style="text-decoration: underline;"><strong>CDC recommendations</strong></span><br>1. At 35-37 weeks’ gestation, all pregnant women should undergo screening with a vaginal and rectal swab for culture.<br>2. If the culture result is positive, the woman should be treated during labor <br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span><br>1. During labor and until delivery, IV penicillin G or ampicillin <br>2. In penicillin-allergic patients at low risk for anaphylaxis, IV cefazolin; in those at high risk for anaphylaxis, IV clindamycin or erythromycin <br>3. The neonate must be carefully observed for signs and symptoms of disease</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>14. </span> A 33-year-old woman presents with foul smelling vaginal discharge. Wet mount and KOH prep are performed demonstrating clue cells. What is the treatment of choice for this patient? </p><ol class=mt-3 type=A><li>Pencillin G</li><li>Reassurance</li><li>Oral metronidazole</li><li>Ceftriaxone</li></ol><button aria-controls=explanation-A75 aria-expanded=false class="btn btn-secondary" data-target=#explanation-A75 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-A75><p class=correct-answer><strong>Answer:</strong> C</p>1. Bacterial vaginosis is vaginitis due to a complex alteration of vaginal flora in which lactobacilli decrease and anaerobic pathogens overgrow. <br>2. Symptoms include a gray, thin, fishy-smelling vaginal discharge and itching. <br>3. Diagnosis is confirmed by testing vaginal secretions. <br>4. Treatment is usually with oral or topical metronidazole or topical clindamycin.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>15. </span> A 30-year-old woman presents to the physician with painful, itchy vascular lesion on the vulvular area, low­-grade fever, cervical motion tenderness,and thin white vaginal discharge . Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Syphilis</li><li>Candidiasis</li><li>Herpes simplex infection</li><li>Herpes Zoster</li></ol><button aria-controls=explanation-LY3 aria-expanded=false class="btn btn-secondary" data-target=#explanation-LY3 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-LY3><p class=correct-answer><strong>Answer:</strong> C</p><span style="text-decoration: underline;"><strong>Herpes Simplex Virus (HSV) </strong></span><br><br>1. HSV is transmitted via close personal contact.<br>2. HSV-1 is transmitted chiefly by contact with infected saliva, whereas HSV-2 is transmitted sexually or from a mother's genital tract infection to her newborn. However, lesion location does not always indicate viral type.<br><br><span style="text-decoration: underline;"><strong>Types</strong></span>:<br> 1. <strong>Type I:</strong> Ophthalmic and oral lesions. <br>2. <strong>Type II:</strong> Genital lesions. <br><br><span style="text-decoration: underline;"><strong>Clinical picture</strong></span>: Small painful vesicles around mouth (HSV-1) or genitals (HSV-2)  lasting several days; primary infection usually presents with more severe symptoms and a flulike illness; disease affecting eyes causes impaired vision; disease affecting esophagus causes odynophagia and dysphagia <br><br><span style="text-decoration: underline;"><strong>Diagnosis</strong></span>: Tzank smear shows multinucleated giant cells, and intranuclear inclusion bodies. <br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span>: Incurable, so treatment should be directed at minimizing symptoms and exacerbations; acyclovir, famciclovir, or valacyclovir shortens duration of recurrences and may decrease number of recurrences in patients with frequent eruptions; therapy can either be intermittent (episodic) or continuous (suppressive) .</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>16. </span> Which of the following medications is safe during breast-feeding? </p><ol class=mt-3 type=A><li>Tetracycline</li><li>Bromocriptine</li><li>Penicillin</li><li>Ciprofloxacin</li></ol><button aria-controls=explanation-DHV aria-expanded=false class="btn btn-secondary" data-target=#explanation-DHV data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DHV><p class=correct-answer><strong>Answer:</strong> C</p>Certain medications are contraindicated during breast-feeding, including quinolone antibiotics, tetracycline, chloramphenicol, bromocriptine, cyclosporine, cyclophosphamide, doxorubicin, methotrexate, lithium, and ergotamine. Other drugs that have relative contraindications include metronidazole, sulfonamides, salicylates, phenobarbital, other psychotropic medication, and antihistamines. Caffeine in large amounts should also be avoided. In addition, recreational drugs (e.g., alcohol, cocaine, marijuana) should be avoided.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>17. </span> A 25-year-old woman comes to the doctor with vaginal discharge and vulvar pruritus. Examination shows a thin, malodorous green vaginal discharge.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Chlamydia</li><li>Candida vaginitis</li><li>Trichomonas vaginalis</li><li>Bacterial vaginosis</li></ol><button aria-controls=explanation-3WW aria-expanded=false class="btn btn-secondary" data-target=#explanation-3WW data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-3WW><p class=correct-answer><strong>Answer:</strong> C</p>1. <span style="text-decoration: underline;"><strong>Trichomonas vaginitis</strong></span> is a sexually transmitted infection that classically presents with yellow-green, malodorous, thin, frothy, and occasionally purulent vaginal discharge. <br>2. It usually causes pruritus, dysuria, and dyspareunia,though it can be asymptomatic.<br>3. Wet mount microscopy would show highly motile pear-shaped organisms with 3-5 flagella. <br>4. Vaginal ph 5.0 – 6.0. <br>5. <strong>Metronidazole</strong> is the treatment of choice and should be prescribed to both the patient and the partner.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>18. </span> Which of the following is responsible for reducing the incidence of neural tube defects? </p><ol class=mt-3 type=A><li>Folate</li><li>Vitamin B1</li><li>Vitamin B12</li><li>Vitamin D</li></ol><button aria-controls=explanation-8NF aria-expanded=false class="btn btn-secondary" data-target=#explanation-8NF data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-8NF><p class=correct-answer><strong>Answer:</strong> A</p>Neural tube defects (NTD) occur because of a defect in the neurulation process. Since the anterior and posterior neuropores close last, they are the most vulnerable to defects. <br><br>Folate supplementation is currently advised for all pregnant women in an attempt to reduce the incidence of neural tube defects (NTDs). <br><br>NTDs can be classified, based on embryological considerations and the presence or absence of exposed neural tissue, as open or closed types.<br>1. Open NTDs frequently involve the entire CNS <br>2. Closed NTDs are localized and confined to the spine</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>19. </span> A 16-year-old girl is brought to the physician by her mother because she has not started to menstruate yet. Examination shows Tanner stage IV breast development and pubic hair, normal external female genitalia, and shaved axillary hair. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Complete androgen insensitivity syndrom</li><li>Mullerian agenesis</li><li>Transverse vaginal septum</li><li>Turner syndrom</li></ol><button aria-controls=explanation-EMB aria-expanded=false class="btn btn-secondary" data-target=#explanation-EMB data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-EMB><p class=correct-answer><strong>Answer:</strong> B</p><span style="text-decoration: underline;"><strong>Mullerian agenesis<br></strong></span><br>1. 46 XX (no uterus)<br>2. Normal female phenotype Normal testosterone <br>3. They experience breast development and body hair grown at puberty but do not menstruate due to a congenitally absent or underdeveloped uterus, cervix, and upper vagina.<br>4. Normal pubic and axillary hair and female testosterone levels</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>20. </span> Which of the following is administered to patients with preeclampsia to prevent seizures? </p><ol class=mt-3 type=A><li>Phenytoin</li><li>Lorazepam</li><li>Magnesium sulfate</li><li>Labetalol</li></ol><button aria-controls=explanation-SHQ aria-expanded=false class="btn btn-secondary" data-target=#explanation-SHQ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-SHQ><p class=correct-answer><strong>Answer:</strong> C</p>1. <span style="text-decoration: underline;"><strong>Preeclampsia</strong></span> refers to the new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman. <br>2. <span style="text-decoration: underline;"><strong>Eclampsia</strong></span> refers to the development of grand mal seizures in a woman with preeclampsia, in the absence of other neurologic conditions that could account for the seizure.<br>3. The basic principles of <strong>airway</strong>, <strong>breathing</strong>, and <strong>circulation</strong> (<strong>ABC</strong>) should always be followed as a general principle of seizure management.<br>4. <strong>Magnesium sulfate is the first-line treatment</strong> for the prevention of primary and recurrent eclamptic seizures. <br>5.For eclamptic seizures that are refractory to magnesium sulfate, <strong>lorazepam</strong> and <strong>phenytoin</strong> may be used as<strong> second-line agents.</strong></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>21. </span> Which of the following is a risk factor for endometriosis? </p><ol class=mt-3 type=A><li>Late-Onset Menopause</li><li>Multiparity</li><li>Human papillomavirus</li><li>Early menarche</li></ol><button aria-controls=explanation-ABB aria-expanded=false class="btn btn-secondary" data-target=#explanation-ABB data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ABB><p class=correct-answer><strong>Answer:</strong> D</p>1. Endometriosis is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity.<br>2. Approximately 30-40% of women with endometriosis will be subfertile.<br>3. Patients with endometriosis do not frequently have any physical examination findings beyond tenderness related to the site of involvement.<br>4. The most common finding is nonspecific pelvic tenderness.<br>5. Laparoscopy is considered the primary diagnostic modality for endometriosis. This is an invasive procedure with an overall sensitivity of 97% but with a specificity of only 77%.<br><br>Risk factors include:<br>1. Nulliparity <br>2. Early menarche <br>3. Shorter menstrual cycles <br>4. Menstrual outflow obstruction</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>22. </span> Which of the following is the most common primary symptom of premenstrual dysphoric disorder? </p><ol class=mt-3 type=A><li>Breast tenderness</li><li>Hypersomnia</li><li>Bloating</li><li>Irritability</li></ol><button aria-controls=explanation-VGN aria-expanded=false class="btn btn-secondary" data-target=#explanation-VGN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-VGN><p class=correct-answer><strong>Answer:</strong> D</p>1. The most common primary symptom of premenstrual dysphoric disorder (PMDD) is <strong>irritability</strong>. The common symptoms of breast pain and bloating differ from those of women with a major depressive disorder.<br>2. Premenstrual dysphoric disorder (PMDD) is a diagnosis used to indicate serious premenstrual distress with associated deterioration in functioning.<br>3. PMDD is characterized by depressed or labile mood, anxiety, irritability, anger, and other symptoms occurring exclusively during the 2 weeks preceding menses. <br>4. <strong>Clinical features</strong>: Weight gain, headache, abdominal or pelvic pain, abdominal bloating, change in bowel habits, food cravings, mood lability, depression, fatigue, irritability; breast tenderness, edema, abdominal tenderness, acne <br>5. Findings precede menses and occur at similar time points in each cycle <br>6. <strong>SSRIs</strong> are the treatment of choice. SSRIs increase extracellular serotonin by blocking the presynaptic receptor.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>23. </span> Which of the following is the most common symptom of placenta previa? </p><ol class=mt-3 type=A><li>Uterine tenderness.</li><li>Back pain</li><li>Abdominal pain</li><li>Vaginal Bleeding</li></ol><button aria-controls=explanation-SFO aria-expanded=false class="btn btn-secondary" data-target=#explanation-SFO data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-SFO><p class=correct-answer><strong>Answer:</strong> D</p>1. Placenta previa is an obstetric complication that classically presents as painless vaginal bleeding in the third trimester secondary to an abnormal placentation near or covering the internal cervical os. <br>2. The most common symptom of placenta previa is vaginal bleeding that is bright red and not associated with abdominal tenderness or pain, especially in the third trimester of pregnancy.<br>3. Ultrasound is the method of choice for diagnosis.<br>4. Pelvic examination is contraindicated in any patient with antepartum hemorrhage until placenta previa is ruled out by ultrasound. <br>5. The management of placenta previa depends on the gestational age of the fetus and the severity of the bleeding.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>24. </span> Which of the following is true about adenomyosis? </p><ol class=mt-3 type=A><li>The presence of endometrial glands and stroma outside of the uterine cavity.</li><li>The presence of endometrial glands in the uterine muscle</li><li>Defined as menstrual bleeding with abnormal duration, quantity, or schedule.</li><li>Defined as prolonged or heavy menstruation, typically lasting longer than 7 days or exceeding 80 ml.</li></ol><button aria-controls=explanation-EUA aria-expanded=false class="btn btn-secondary" data-target=#explanation-EUA data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-EUA><p class=correct-answer><strong>Answer:</strong> B</p>1. <span style="text-decoration: underline;"><strong>Adenomyosis</strong></span> is defined as the presence of endometrial glands in the uterine muscle. This invasion can extend to the full thickness of the myometrium, or in some instances, to the serosa of the uterus.<br>2. Adenomyosis occurs most frequently in women above 40 and typically presents with severe dysmenorrhea and menorrhagia. <br>3. Examination reveals an enlarged and generally symmetrical uterus.<br>4. <strong>Treatment</strong>: Largely symptomatic relief. NSAIDs (first line) plus OCPs or progestins. <br>5. <strong>Hysterectomy</strong> is the only definitive treatment.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>25. </span> Which of the following is true about HELLP syndrome? </p><ol class=mt-3 type=A><li>Hemolysis, Low Liver enzymes, High Platelet count</li><li>Hypotension, Elevated Liver enzymes, Low Platelet count</li><li>Hypertension, Elevated Liver enzymes, Low Platelet count</li><li>Hemolysis, Elevated Liver enzymes, Low Platelet count</li></ol><button aria-controls=explanation-X4G aria-expanded=false class="btn btn-secondary" data-target=#explanation-X4G data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-X4G><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>HELLP syndrome</strong>, named for 3 features of the disease (hemolysis, elevated liver enzyme levels, and low platelet levels), is a life-threatening condition that can potentially complicate pregnancy.<br>2. HELLP syndrome is a potential manifestation of severe preeclampsia. <br>3. HELLP syndrome typically occurs between 27 weeks’ gestation and delivery in women with a mean age of 25 years.<br>4. Symptoms include: Right upper quadrant or epigastric pain &amp; nausea or vomiting (30%-90% of patients) malaise, weight gain, and various other nonspecific symptoms<br><br>Risk factors for HELLP syndrome include the following:<br>1. Maternal age older than 34 years <br>2. Multiparity <br>3. History of poor pregnancy outcome</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>26. </span> What is the most important risk factors for endometrial carcinoma? </p><ol class=mt-3 type=A><li>Unopposed estrogen</li><li>Nulliparity</li><li>Pregnancy</li><li>Smoking</li></ol><button aria-controls=explanation-2AX aria-expanded=false class="btn btn-secondary" data-target=#explanation-2AX data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-2AX><p class=correct-answer><strong>Answer:</strong> A</p><span style="text-decoration: underline;"><strong>Risk factors for endometrial carcinoma:</strong></span><br>1. Unopposed estrogen or prolonged use of tamoxifen<br>2. Advancing age<br>3. Obesity<br>4. Nulliparity<br>5. Anovulatory conditions (eg, polycystic ovarian syndrome). <br><br>The most important risk factors for endometrial carcinoma are unopposed estrogen states</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>27. </span> A 71-year-old female present with vaginal dryness, burning and dyspareunia. She also has dysuria and increased urinary frequency. The symptoms have been present for several months but have intensified recently. Physical examination shows scarce pubic hair and reduced elasticity and turgor of the vulvar skin. Pale, dry and smooth vaginal epithelium is noted. Urine dipstick is normal. Which of the following is treatment of choice for this patient?<br><br><br> </p><ol class=mt-3 type=A><li>Metronidazole vaginal gel</li><li>Estrogen vaginal cream</li><li>Topical corticosteroid cream</li><li>Clotrimazole vaginal cream</li></ol><button aria-controls=explanation-C6J aria-expanded=false class="btn btn-secondary" data-target=#explanation-C6J data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-C6J><p class=correct-answer><strong>Answer:</strong> B</p>1. <span style="text-decoration: underline;"><strong>Atrophic vaginitis</strong></span> may present with vaginal itching, burning, pain, dryness, or dysparunia.<br>2. In the absence of estrogen, the vaginal mucosa thins, has diminished blood supply and vaginal secretions, and there can be loss of connective tissues that provide pelvic support.<br>3. Treatment of the postmenopausal woman for atrophic vaginitis includes replacing estrogen, either orally or topically with vaginal creams.<br>4. Vaginal creams may help in alleviating local symptoms but do not provide enough systemic absorption to be relied on for the beneficial effects of estrogens on osteoporosis.<br>5. Oral estrogens must be used in concert with progesterone in order to avoid the risks of endometrial hyperplasia and cancer in women with an intact uterus.<br>6. Before providing oral estrogen therapy, careful consideration of the risks and benefits should be discussed with the patient. Potential risks include cardiovascular and venous thromboembolic disease as well as slight increased risk for both endometrial and breast cancer. <br>7. Topical corticosteroids, metronidazole gel, clotrimazole cream, and douching provide no benefit in treating atrophic vaginitis.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>28. </span> Which of the following medications is the initial therapy for a pregnant mother with essential hypertension? </p><ol class=mt-3 type=A><li>Methyldopa</li><li>Furosemide</li><li>Lisinopril</li><li>Losartan</li></ol><button aria-controls=explanation-1GC aria-expanded=false class="btn btn-secondary" data-target=#explanation-1GC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-1GC><p class=correct-answer><strong>Answer:</strong> A</p>Hypertension is the most common medical problem encountered during pregnancy.<br><br><strong>Hypertension during pregnancy can be classified into 4 categories :</strong><br><br>1.<strong> Gestational hypertension</strong> : High blood pressure first <span style="text-decoration: underline;">detected after 20 weeks of gestation</span> in the absence of proteinuria or other diagnostic features of preeclampsia.<br><br>2. <strong>Chronic hypertension</strong> : High blood pressure (SBP ≥ 140 mmHg , DBP ≥90 mmHg ) which is <span style="text-decoration: underline;">present before the 20th week of pregnancy</span>, or persists longer than 12 weeks postpartum.<br><br>3. <strong>Preeclampsia-eclampsia</strong><br>4. <strong>Preeclampsia superimposed on chronic hypertension</strong><br><br>Antihypertensive during pregnancy <br><br><strong>First Line :</strong><br>1. Methyldopa <br><br>2. Beta blockers (IV labetalol : considered first-line medications for the management of acute-onset , labetalol should be avoided in women with asthma, heart disease, or congestive heart failure. )<br><br>3. Hydralazine (IV Hydralazine : considered first-line medications for the management of acute-onset) Calcium channel blockers (e.g nifedipine) <br><br><strong>Second-line<br></strong>Thiazide diuretics<br><br><strong>Contraindicated<br></strong>1. ACE inhibitors e.g lisinopril<br>2. Furosemide ARB e.g losartan<br>3. Aldosterone blockers</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>29. </span> Valproic acid intake during pregnancy increases the risk of which of the following? </p><ol class=mt-3 type=A><li>Neural tube defect</li><li>Low birth weight</li><li>Anencephaly</li><li>Kernicterus</li></ol><button aria-controls=explanation-YGM aria-expanded=false class="btn btn-secondary" data-target=#explanation-YGM data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-YGM><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Neural tube defects</strong> (NTD) occur because of a defect in the neurulation process.<br>2. The frequency of NTDs is increased with exposure to certain environmental factors, such as drugs (<strong>valproic acid,</strong> carbamazepine , folic acid antagonists eg, [ methotrexate , aminopterin], excessive vitamin A intake), hyperthermia, maternal diabetes mellitus, obesity, and folate deficiency.<br>3. <strong>Ultrasound</strong> is also an effective technique for detecting NTDs,</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>30. </span> Which of the following is the treatment of choice for a patient with Neisseria gonorrhoeae? </p><ol class=mt-3 type=A><li>Penicillin and doxycycline</li><li>Ceftriaxone and azithromycin</li><li>Ceftriaxone and metronidazole</li><li>Ceftriaxone</li></ol><button aria-controls=explanation-99D aria-expanded=false class="btn btn-secondary" data-target=#explanation-99D data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-99D><p class=correct-answer><strong>Answer:</strong> B</p>Neisseria gonorrhoeae is the second most common cause of cervicitis after Chlamydia trachomatis. Treatment includes a 3rd-generation cephalosporin in combination with azithromycin or doxycycline. The second agent provides empiric coverage for cephalosporin-resistant gonococci as well as C trachomatis.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>31. </span> What is the gestational age for screening group B Streptococcus? </p><ol class=mt-3 type=A><li>10–15 weeks</li><li>35–37 weeks</li><li>30–32 weeks</li><li>25–30 weeks</li></ol><button aria-controls=explanation-JV5 aria-expanded=false class="btn btn-secondary" data-target=#explanation-JV5 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-JV5><p class=correct-answer><strong>Answer:</strong> B</p>1. Screening cultures for group B streptococcus should be performed at 36-37 weeks gestation.<br>2. Positive cases should be treated with penicillin G during labor.<br><br> <table class="table table-responsive table-sm table-striped"> <tbody> <tr> <td><strong>Initial visit</strong></td> <td>1. CBC<br>2. Urinalysis<br>3. Blood antibody and Rh typing<br>4. Pap smear<br>5. Gonorrhea + chlamydia screening<br>6. RPR or VDRL<br>7. HIV screening <br>8. Rubella antibody titer<br>9. Hepatitis B surface antigen <br><br></td> </tr> <tr> <td><strong>16–18 weeks</strong></td> <td>Quadruple screen ( Trisomies 21 + 18 + neural tube defects )<br>1. Maternal serum alpha fetoprotein<br>2. hCG<br>3. Maternal serum inhibin A<br>4. Unconjugated estriol<br><br></td> </tr> <tr> <td><strong>18–20 weeks</strong></td> <td>Ultrasound to determine GA and to survey fetal anatomy, amniotic fluid volume, and placental location.</td> </tr> <tr> <td><strong>24–28 weeks</strong></td> <td> Glucose challenge test (screen for gestational DM)<br><br></td> </tr> <tr> <td><strong>32–37 weeks</strong></td> <td>1. <span style="text-decoration: underline;"><strong>Group B streptococcus screening</strong></span> <br>2. Cervical culture for Neisseria gonorrhoeae and Chlamydia trachomatis (Only high-risk patients)</td> </tr> </tbody> </table></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>32. </span> Which of the following is the most sensitive screening method for group B Streptococcus (GBS) ? </p><ol class=mt-3 type=A><li>Culture of the vagina and rectum</li><li>VDRL</li><li>FTA-ABS</li><li>Rapid plasma regain test</li></ol><button aria-controls=explanation-RQ0 aria-expanded=false class="btn btn-secondary" data-target=#explanation-RQ0 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-RQ0><p class=correct-answer><strong>Answer:</strong> A</p>1. Bacterial infections can affect pregnant women from implantation of the fertilized ovum through the time of delivery and peripartum period. They may also affect the fetus and newborn. <br>2. <strong>Group B Streptococcus</strong> (GBS; Streptococcus agalactiae) is the most common cause of life-threatening infections in newborns and can also affect the mother.<br><strong>3. Culture of the vagina and rectum is the most sensitive screening method for GBS. </strong><br><br><strong>CDC recommendations</strong><br>1. At 35-37 weeks’ gestation, all pregnant women should undergo screening with a vaginal and rectal swab for culture.<br>2. If the culture result is positive, the woman should be treated during labor<br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span><br>1. During labor and until delivery, IV penicillin G or ampicillin <br>2. In penicillin-allergic patients at low risk for anaphylaxis, IV cefazolin; in those at high risk for anaphylaxis, IV clindamycin or erythromycin <br>3. The neonate must be carefully observed for signs and symptoms of disease</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>33. </span> Which of the following conditions is associated with strawberry cervix? </p><ol class=mt-3 type=A><li>Herpes simplex virus</li><li>Trichomonas vaginitis</li><li>Gonorrheal cervicitis</li><li>Chlamydia! cervicitis</li></ol><button aria-controls=explanation-YF2 aria-expanded=false class="btn btn-secondary" data-target=#explanation-YF2 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-YF2><p class=correct-answer><strong>Answer:</strong> B</p><strong>Trichomonas vaginitis</strong> <br>1. It usually causes gray-green, thin, frothy vaginal discharge, pruritus, dysuria, and dyspareunia,  though it can be asymptomatic. <br>2. The most common patient complaint is vaginal discharge associated with itching, burning, and pain with intercourse. <br>3. Speculum Examination. Vaginal discharge is typically frothy and green. The vaginal epithelium is frequently edematous and inflamed. The erythematous cervix may demonstrate the characteristic “strawberry” appearance. Vaginal pH is elevated &gt;4.5. <br>4. Metronidazole is the treatment of choice and should be prescribed to both the patient and the partner. <br>5. Metronidazole is safe to use during pregnancy, including the first trimester.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>34. </span> What is the best test in diagnosing cystic breast masses?<br><br> </p><ol class=mt-3 type=A><li>Ultrasound</li><li>Mammograms</li><li>Computed tomography</li><li>Magnetic resonance imaging</li></ol><button aria-controls=explanation-Y1O aria-expanded=false class="btn btn-secondary" data-target=#explanation-Y1O data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-Y1O><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Cystic breast lesions</strong> are commonly observed at ultrasonography (US) performed for the evaluation of palpable or mammographically detected breast masses. Complex cysts contain cystic and solid components and are associated with a variety of benign, atypical, and malignant pathologic diagnoses.<br>2. <strong>Breast MRI</strong> Is performed In patients with known cancer to evaluate for disease recurrence and to screen for breast cancer in high-risk patients (eg, BRCA carrier, first-degree relative of known BRCA carrier). MRI is expensive and unnecessary for breast cyst surveillance. <br>3. Annual <strong>mammograms</strong> and clinical breast examinations are recommended for women older than 40 years.<br>4. <strong>Ultrasonographic</strong> studies are most useful to evaluate cystic breast masses. <br>5. For solid masses, diagnostic biopsy techniques include <span style="text-decoration: underline;">fine-needle aspiration</span>, core biopsy, and excisional biopsy.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>35. </span> Which of the following conditions is a contraindication to breastfeeding? </p><ol class=mt-3 type=A><li>Smoking</li><li>Active untreated TB</li><li>Hepatitis B-positive mothers</li><li>Hepatitis C-positive mothers</li></ol><button aria-controls=explanation-HBS aria-expanded=false class="btn btn-secondary" data-target=#explanation-HBS data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-HBS><p class=correct-answer><strong>Answer:</strong> B</p><strong>The following are considered definitive contraindications to breastfeeding:</strong><br><br>1. Active untreated TB <br>2. Maternal HIV infection <br>3. Herpetic breast lesions<br>4. Varicella infection &lt;5 days before or 2 days after delivery <br><!--5-->5. Chemotherapy<br>6. Undergoing radiation therapies<br>7. Active abuse of alcohol or drugs <br>8. An infant diagnosed with galactosemia (galactose 1-phosphate uridyltransferase deficiency)<br><br><br><strong>Hepatitis C</strong> is not a contraindication for breastfeeding, but reconsider if nipples are cracked or bleeding.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>36. </span> A 30-year-old woman comes to the doctor with severe pain during sexual intercourse. She also complains of dysmenorrhea, and pain with defecation. She and her husband have had frequent unprotected sexual intercourse for over a year. Laboratory studies are normal.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Ovarian cancer</li><li>Pelvic congestion syndrome</li><li>Endometriosis</li><li>Adenomyosis</li></ol><button aria-controls=explanation-RRL aria-expanded=false class="btn btn-secondary" data-target=#explanation-RRL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-RRL><p class=correct-answer><strong>Answer:</strong> C</p>1. <span style="text-decoration: underline;"><strong>Endometriosis</strong></span> is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity<br>2. Can be found anywhere; most common sites are ovary (frequently bilateral), pelvis, peritoneum. In ovary, appears as endometrioma (blood-flled “chocolate cyst”). <br>3. <strong>Characterized</strong> by cyclic pelvic pain, bleeding, dysmenorrhea, dyspareunia, dyschezia (pain with defecation), infertility; normal-sized uterus. <br>4. <strong>Laparoscopy is the gold standard</strong> for the diagnosis of endometriosis. <br>5. Treatment: NSAIDs, OCPs, progestins, GnRH agonists, danazol, laparoscopic removal.<br>6.  <strong>Oral contraceptive pills are first line agents in the treatment of endometriosis in young women desiring future fertility.  </strong></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>37. </span> Intrauterine Device (IUD) is contraindicated in which of the following? </p><ol class=mt-3 type=A><li>Pelvic Inflammatory Disease</li><li>Migraine headaches</li><li>Ectopic pregnancy</li><li>Endometriosis</li></ol><button aria-controls=explanation-9U7 aria-expanded=false class="btn btn-secondary" data-target=#explanation-9U7 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-9U7><p class=correct-answer><strong>Answer:</strong> A</p>Absolute contraindications for IUD use include the following:<br>1. Pregnancy<br>2. Significantly distorted uterine anatomy<br>3. Unexplained vaginal bleeding concerning for pregnancy or pelvic malignancy<br>4. Gestational trophoblastic disease with persistently elevated beta-human chorionic gonadotropin levels<br>5. Ongoing pelvic infection <br><br>IUD use is safe in women with the following conditions:<br>1. History of an ectopic pregnancy<br>2. History of pelvic surgery<br>3. Hypertension or other forms of heart disease<br>4. History of deep venous thrombosis<br>5. History of migraine headaches<br>6. Anemia<br>7. Diabetes<br>8. Endometriosis<br>9. Smoking</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>38. </span> A patient with polycystic ovarian syndrome is at greater risk of which of the following conditions? </p><ol class=mt-3 type=A><li>Vaginal cancer</li><li>Ovarian cancer</li><li>Breast cancer</li><li>Endometrial carcinoma</li></ol><button aria-controls=explanation-BGN aria-expanded=false class="btn btn-secondary" data-target=#explanation-BGN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-BGN><p class=correct-answer><strong>Answer:</strong> D</p>Polycystic ovary syndrome is a clinical syndrome characterized by mild obesity, irregular menses or amenorrhea, and signs of androgen excess (eg, hirsutism, acne). In most patients, the ovaries contain multiple cysts.<br><br>Patients with PCOS are at high risk to develop endometrial hyperplasia and endometrial carcinoma due to unbalanced estrogen secretion.<br><br>The major features of PCOS include menstrual dysfunction, anovulation, and signs of hyperandrogenism.<br>Other signs and symptoms of PCOS may include the following:<br>1. Hirsutism<br>2. Infertility<br>3. Obesity and metabolic syndrome<br>4. Diabetes<br>5. Obstructive sleep apnea<br><br>On examination, findings in women with PCOS may include the following:<br>1. Virilizing signs <br>2. Acanthosis nigricans <br>3. Hypertension <br>4. Enlarged ovaries: May or may not be present; evaluate for an ovarian mass <br><br>Lifestyle modifications are considered first-line treatment for women with PCOS. Such changes include the following:<br>1. Diet <br>2. Exercise <br>3. Weight loss <br><br>Pharmacologic treatments are reserved for so-called metabolic derangements, such as anovulation, hirsutism, and menstrual irregularities. First-line medical therapy usually consists of an oral contraceptive to induce regular menses.<br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>39. </span> Which of the following medications is associated with an increased risk of endometrial carcinoma? </p><ol class=mt-3 type=A><li>Progesterone</li><li>Oral contraceptives</li><li>Tamoxifen</li><li>Bromocriptine</li></ol><button aria-controls=explanation-BEL aria-expanded=false class="btn btn-secondary" data-target=#explanation-BEL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-BEL><p class=correct-answer><strong>Answer:</strong> C</p>1. Endometrial cancer is usually endometrioid adenocarcinoma.<br>2. Typically, postmenopausal vaginal bleeding occurs.<br>3. Approximately 75% of women with endometrial cancer are postmenopausal. Thus, the most common symptom is postmenopausal bleeding.<br>4. Endometrial cancer is more common in developed countries where the diet is high in fat. <br>5. Diagnosis is by biopsy. <br>6. Staging is surgical. (Stage endometrial cancer surgically via laparotomy, laparoscopy, or a robotic-assisted surgery.)<br>7. Treatment requires hysterectomy, bilateral salpingo-oophorectomy, and, in high-risk patients, usually pelvic and para-aortic lymphadenectomy. <br>8. For advanced cancer, radiation, hormone, or cytotoxic therapy is usually indicated.<br><br><strong>Major risk factors for endometrial cancer are:</strong><br>1. Unopposed estrogen<br>2. Age &gt; 50<br>3. Obesity<br>4. Diabetes<br><br><strong>Other risk factors include</strong><br>1. Tamoxifen use for &gt; 5 yr<br>2. Previous pelvic radiation therapy<br>3. A personal or family history of breast or ovarian cancer<br>4. Family history of hereditary nonpolyposis colorectal cancer or possibly, among 1st-degree relatives, endometrial cancer<br>5. Hypertension</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>40. </span> A 28-year-old woman presents to the doctor with high fever, dysuria, flank pain, nausea, and vomiting. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Urinary tract infections</li><li>Perinephric Abscess</li><li>Gonorrhea</li><li>Acute pyelonephritis</li></ol><button aria-controls=explanation-9JX aria-expanded=false class="btn btn-secondary" data-target=#explanation-9JX data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-9JX><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Pyelonephritis</strong></span> <br>1. Infection of renal parenchyma most commonly caused by Escherichia coli; Staphylococcus saprophyticus, Klebsiella, and Proteus are less common pathogens; Candida is a potential cause in immunocompromised patients.<br>2. <strong>Escherichia coli</strong> accounts for more than 70% of cases.<br>3. Most commonly occurs as sequelae of ascending urinary tract infection (UTI).<br>4. In pregnant patients, asymptomatic bacteruiria increases the risk of developing cystitis and pyelonephritis more than in the non-pregnant state.<br>5. <strong>Asymptomatic bacteruiria</strong> is a positive urine culture in the absence of urinary tract symptoms. <br>6. <strong>Risk factors</strong>: urinary obstruction, immunocompromise, history of previous pyelonephritis, diabetes mellitus (DM), sexual intercourse &gt;3 times/week, spermicide use<br>7. <strong>Clinical features</strong>: flank pain, chills, nausea, vomiting, urinary frequency, dysuria, urgency; fever (38°C), costovertebral tenderness<br>8. <strong>Recommended antibiotics</strong> in pregnancy are ampicillin, nitrofurantoin, or first generation oral cephalosporins. <br>9. <strong>Complications</strong>: increased risk of preterm labor and low birth weight in pregnant women</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>41. </span> A 33-year-old woman at 10 weeks gestation presents to the emergency room with vaginal bleeding and lower abdominal pain. Examination shows an effaced and dilated cervix with visible products of conception.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Complete abortion</li><li>Inevitable abortion</li><li>Missed abortion</li><li>Threatened abortion</li></ol><button aria-controls=explanation-MNO aria-expanded=false class="btn btn-secondary" data-target=#explanation-MNO data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-MNO><p class=correct-answer><strong>Answer:</strong> B</p><span style="text-decoration: underline;"><strong>Inevitable abortion</strong></span> presents as vaginal bleeding, lower abdominal cramps, and a dilated cervix. Ultrasound  shows a ruptured/collapsed gestational sac with no fetal cardiac motion.<br><br><span style="text-decoration: underline;">Types of Spontaneous Abortions</span><br> <table class="table table-responsive table-sm table-striped"> <tbody> <tr> <td><span style="text-decoration: underline;"><strong>Type</strong></span></td> <td><span style="text-decoration: underline;"><strong>Threatened</strong></span></td> <td><span style="text-decoration: underline;"><strong>Missed</strong></span></td> <td><span style="text-decoration: underline;"><strong>Inevitable</strong></span></td> <td><span style="text-decoration: underline;"><strong>Incomplete</strong></span></td> <td><span style="text-decoration: underline;"><strong>Complete</strong></span></td> </tr> <tr> <td><strong>Uterine bleeding</strong></td> <td>Initial 20 wk of gestation </td> <td>Present or with pain</td> <td>Initial 20 wk pain</td> <td>Initial 20 wk</td> <td>Initial 20 wk</td> </tr> <tr> <td><strong>Cervical os</strong></td> <td>Closed</td> <td>Closed</td> <td>Open</td> <td>Open</td> <td>Open or closed</td> </tr> <tr> <td><strong>Uterine contents expelled</strong></td> <td>None</td> <td>None</td> <td>None</td> <td>Some</td> <td>All</td> </tr> <tr> <td><strong>Diagnosis</strong></td> <td>US detects viable fetus, cervix is closed</td> <td>US detects nonviable intrauterine fetu</td> <td>Viable fetus, cervix is dilated</td> <td>Based on history of expelled products of conception</td> <td>Based on history of expelled products of conception</td> </tr> </tbody> </table></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>42. </span> Which of the following is the drug of choice for controlling eclamptic seizures? </p><ol class=mt-3 type=A><li>Magnesium sulfate</li><li>Phenobarbital</li><li>Phenytoin</li><li>Diazepam</li></ol><button aria-controls=explanation-4JT aria-expanded=false class="btn btn-secondary" data-target=#explanation-4JT data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-4JT><p class=correct-answer><strong>Answer:</strong> A</p>1. Preeclampsia is new-onset hypertension and proteinuria after 20 wk gestation.<br>2. Eclampsia is unexplained generalized seizures in patients with preeclampsia. <br>3. As soon as eclampsia or severe preeclampsia is diagnosed, Mg sulfate must be given to stop or prevent seizures and reduce reflex reactivity.<br>4. Magnesium sulfate is used for the prevention of eclamptic seizures. In mild preeclampsia, it is  administrated during labor and within 24 hours of delivery. <br>5. The main inconvenience of magnesium sulfate is its toxicity; it manifests with hyporeflexia “depressed  deep tendon reflexes” (first sign), respiratory depression, CNS depression, coma, and death by  cardiac arrest. <br>6. The treatment of MgSO4 toxicity is to immediately stop the infusion then to administer calcium  gluconate.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>43. </span> What is the  average length of the menstrual cycle? </p><ol class=mt-3 type=A><li>35</li><li>25</li><li>28</li><li>30</li></ol><button aria-controls=explanation-OQP aria-expanded=false class="btn btn-secondary" data-target=#explanation-OQP data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-OQP><p class=correct-answer><strong>Answer:</strong> C</p><br>1. Menstruation is the periodic discharge of blood and sloughed endometrium (collectively called menses or menstrual flow) from the uterus through the vagina. It is caused by the rapid decline in ovarian production of progesterone and estrogen that occurs each cycle in the absence of a pregnancy. Menstruation occurs throughout a woman’s reproductive life in the absence of pregnancy.<br>2. Menopause is the permanent cessation of menses.<br>3. Average duration of menses is 5 (± 2) days. Blood loss per cycle averages 30 mL (normal range, 13 to 80 mL) and is usually greatest on the 2nd day. A saturated pad or tampon absorbs 5 to 15 mL. Menstrual blood does not usually clot (unless bleeding is very heavy), probably because fibrinolysin and other factors inhibit clotting.<br><br>4. The median menstrual cycle length is 28 days (usual range, about 25 to 36 days). Generally, variation is maximal and intermenstrual intervals are longest in the years immediately after menarche and immediately before menopause, when ovulation occurs less regularly. The menstrual cycle begins and ends with the first day of menses (day 1).</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>44. </span> Which of the following is <strong>not</strong> a feature of preeclampsia? </p><ol class=mt-3 type=A><li>Seizures</li><li>Edema</li><li>Elevated blood pressure</li><li>Proteinuria</li></ol><button aria-controls=explanation-QJ2 aria-expanded=false class="btn btn-secondary" data-target=#explanation-QJ2 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-QJ2><p class=correct-answer><strong>Answer:</strong> A</p>1. Preeclampsia is new-onset hypertension and proteinuria after 20 wk gestation. <br>2. Eclampsia is unexplained generalized seizures in patients with preeclampsia. <br>3. Diagnosis is clinical and by urine protein measurement.<br>4. Treatment is usually with IV Mg sulfate and delivery at term.<br>5. The classic preeclamptic triad includes elevated blood pressure, proteinuria, and edema. More recently, edema has been removed as part of the criteria. <br>6. Seizures are the distinguishing component of eclampsia</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>45. </span> Which of the following is associated with snowstorm appearanceon on ultrasound? </p><ol class=mt-3 type=A><li>Multiple Gestations</li><li>Missed abortion</li><li>Choriocarcinoma</li><li>Complete hydatidiform mole</li></ol><button aria-controls=explanation-LS0 aria-expanded=false class="btn btn-secondary" data-target=#explanation-LS0 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-LS0><p class=correct-answer><strong>Answer:</strong> D</p><strong>1. Hydatidiform mole is the most common form of gestational trophoblastic disease.</strong><br>2. It is characterized by the presence of multiple hydropic villi which gives the ultrasonographic appearance of a central heterogeneous mass having a solid, hyper echoic area and interspersed with multitude of cystic areas and filling the entire uterine cavity. <br>3. <span style="text-decoration: underline;"><strong>Ultrasound</strong></span> is primarily used to rule out an intrauterine pregnancy <br>4. Classic sonographic appearance of a complete mole: “<strong>Snowstorm</strong>” or “<strong>granular</strong>” appearance <br>5. <span style="text-decoration: underline;"><strong>Snowstorm sign</strong></span> in obstetric imaging is classically <strong>seen in complete hydatiform mole</strong><br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>46. </span> A 29-year-old female with lower abdominal pain, fever, chills, dysuria, cervical motion tenderness, and adnexal tenderness. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Herpes simplex infection</li><li>Gonococcal urethritis</li><li>Pelvic inflammatory disease</li><li>Bacterial vaginosis</li></ol><button aria-controls=explanation-LA3 aria-expanded=false class="btn btn-secondary" data-target=#explanation-LA3 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-LA3><p class=correct-answer><strong>Answer:</strong> C</p>1.<span style="text-decoration: underline;"><strong> Pelvic inflammatory disease</strong></span> (PID) is an infectious and inflammatory disorder of the upper female genital tract, including the uterus, fallopian tubes, and adjacent pelvic structures.<br>2. <span style="text-decoration: underline;"><strong>Organism</strong></span>: Most commonly caused by Chlamydia trachomatis D and K and/or Neisseria gonorrhea.<br>3. <span style="text-decoration: underline;"><strong>Risk factors</strong></span> 􏰄:multiple sexual partners, unprotected intercourse, prior PID, douching, young age at first intercourse <br>4. <span style="text-decoration: underline;"><strong>Symptoms</strong></span>: Lower abdominal pain starting within days of menses, nausea, vomiting, dysuria; purulent cervical discharge, abdominal tenderness, fever, cervical motion tenderness, adnexal tenderness, possible abdominal guarding <br>5. The diagnosis of acute PID is primarily based on historical and clinical findings.<br>6. <strong>Pregnancy test is the best initial test.</strong><br>7. <strong>Laparoscopy is the most accurate test<br></strong>8. <span style="text-decoration: underline;"><strong>Treatment</strong></span>: Ceftriaxone or cefoxitin plus doxycycline for 2–3 weeks.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>47. </span> A 18-year-old girl presents to the physician with primary amenorrhea. Examination shows normal breast development and minimal axillary and pubic hair. Her external genitalia appear normal but the vagina is short and the cervix is not visible. Bimanual examination confirms the absence of a uterus and cervix and the ovaries are not palpable. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Transverse vaginal septum</li><li>Mullerian agenesis</li><li>Turner syndrome</li><li>Androgen insensitivity syndrome</li></ol><button aria-controls=explanation-3CU aria-expanded=false class="btn btn-secondary" data-target=#explanation-3CU data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-3CU><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Androgen Insensitivity Syndrome </strong></span><br>1. It is <strong>X-­linked disorder</strong><br>2. It is due to defect in androgen receptor gene<br>3. All infants are <strong>46, XY</strong><br>4. All infants have testes and normal testosterone levels<br><br><span style="text-decoration: underline;"><strong>Clinical presentation </strong></span><br>1. Infant is phenotypically female at birth<br>2. Most infants raised as female and identify with female gender<br>3. External genitalia are female and the vagina ends in a blind pouch<br>4. No uterus<br>5. Fallopian tubes may or may not be present<br>6. Testes are usually intra-­abdominal <br>7. At puberty breast develop normally <br>8. No menses <br>9. Sexual hair does not appear <br>10. Normal male adult height <br>11. Testosterone may be normal or high</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>48. </span> Which of the following is the most common cause of secondary dysmenorrhea? </p><ol class=mt-3 type=A><li>Leiomyoma</li><li>Endometriosis</li><li>Ovarian cyst</li><li>Adenomyosis</li></ol><button aria-controls=explanation-NK1 aria-expanded=false class="btn btn-secondary" data-target=#explanation-NK1 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-NK1><p class=correct-answer><strong>Answer:</strong> B</p>1. <span style="text-decoration: underline;"><strong>Dysmenorrhea</strong></span> refers to the symptom of painful menstruation.<br>2. It can be divided into 2 broad categories: <span style="text-decoration: underline;"><strong>primary</strong></span> (occurring in the absence of pelvic pathology) and <span style="text-decoration: underline;"><strong>secondary</strong></span> (resulting from identifiable organic diseases).<br><strong>3. The most common cause of secondary dysmenorrhea is endometriosis.</strong><br>4. Pharmacotherapy is the most reliable and effective treatment for relieving dysmenorrhea. Treatment of secondary dysmenorrhea involves correction of the underlying organic cause.<br><br><span style="text-decoration: underline;"><strong>The following may indicate secondary dysmenorrhea:</strong></span><br>1. Dysmenorrhea beginning in the 20s or 30s, after previous relatively painless cycles <br>2. Heavy menstrual flow or irregular bleeding <br>3. Dysmenorrhea occurring during the first or second cycles after menarche <br>4. Pelvic abnormality with physical examination <br>5. Poor response to nonsteroidal anti-inflammatory drugs (NSAIDs) or oral contraceptives (OCs) <br>6. Infertility <br>7. Dyspareunia <br>8. Vaginal discharge <br><br><br><span style="text-decoration: underline;"><strong>The following risk factors are associated with more severe episodes of dysmenorrhea:</strong></span><br>1. Earlier age at menarche <br>2. Long menstrual periods <br>3. Heavy menstrual flow <br>4. Smoking <br>5. Positive family history</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>49. </span> A 33-year old multigravida at 38 weeks gestation became disoriented, breathless and cyanotic after spontaneous vaginal delivery. The doctor noticed bleeding from the IV line site. Her blood pressure is 75/49 mm Hg, pulse is 120/min, and respirations are 27/min. Oxygen saturation is 70% on facemask.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Myocardial Infarction</li><li>Amniotic fluid embolism</li><li>Abruptio Placentae</li><li>Pulmonary Embolism</li></ol><button aria-controls=explanation-QTR aria-expanded=false class="btn btn-secondary" data-target=#explanation-QTR data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-QTR><p class=correct-answer><strong>Answer:</strong> B</p>1. <span style="text-decoration: underline;"><strong>Amniotic fluid embolism</strong></span> (AFE) is a rare obstetric emergency in which it is postulated that amniotic fluid, fetal cells, hair, or other debris enter the maternal circulation, causing cardiorespiratory collapse.<br>2. Amniotic fluid embolism may occur after amniocentesis or during labor.<br>3. Reported risk factors for development of AFE include multiparity, advanced maternal age, male fetus, and trauma. <br>4.Abrupt onset of hypoxia with respiratory failure, cardiogenic shock and seizures, in a patient who had undergone amniocentesis or delivered, is most likely due to amniotic fluid embolism.<br>5. Disseminated intravascular coagulation (DIC) is the most feared complication in patients with amniotic fluid embolism.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>50. </span> Painless and profuse vaginal bleeding in the third trimester is most likely due to which of the following?<br><br> </p><ol class=mt-3 type=A><li>Placenta acreda</li><li>Vasa praevia</li><li>Cord prolapse</li><li>Placenta previa</li></ol><button aria-controls=explanation-053 aria-expanded=false class="btn btn-secondary" data-target=#explanation-053 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-053><p class=correct-answer><strong>Answer:</strong> D</p>1. Placenta previa is implantation of the placenta over or near the internal os of the cervix. Typically, painless vaginal bleeding with bright red blood occurs after 20 wk gestation.<br>2. Although spotting may occur during the first and second trimesters of pregnancy, the first episode of hemorrhage usually begins at some point after the 28th week and is characteristically described as being sudden, painless, and profuse.<br>3. Painless hemorrhage is the hallmark sign of placenta previa.<br>4. Diagnosis is by transvaginal or abdominal ultrasonography. <br>5. Treatment is bed rest for minor vaginal bleeding before 36 wk gestation, with cesarean delivery at 36 wk if fetal lung maturity is documented. <br>6. If bleeding is severe or refractory or if fetal status is nonreassuring, immediate delivery, usually cesarean, is indicated.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>51. </span> A 30-year-old gravida 3 para 2 presents with a pain in her flank, fever and chills. Lab results reveal positive urinalysis (presence of nitrites and white blood cells). Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Cervicitis</li><li>Urinary Tract Infection</li><li>Cystitis</li><li>Pyelonephritis</li></ol><button aria-controls=explanation-FPL aria-expanded=false class="btn btn-secondary" data-target=#explanation-FPL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-FPL><p class=correct-answer><strong>Answer:</strong> D</p>Pyelonephritis<br>1. Patient presents with urinary frequency, urgency, burning, and dysuria in the<br>2. same way as cystitis, and there is flank pain and tenderness. Pyelonephritis<br>3. is also a more severe disease, so there is a higher fever and the patient is much<br>4. more ill.<br>5. Diagnostic: Urinalysis and urine culture the same as for cystitis<br>6. Treatment: Any of the medications for gram-negative bacilli are effective. Ciprofloxacin is recommended for outpatient treatment. <br>7. For inpatient therapy use ceftriaxone, ertapenem, quinolones, ampicillin, and gentamicin.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>52. </span> Which of the following is the treatment of choice for bacterial vaginosis? </p><ol class=mt-3 type=A><li>Azithromycin</li><li>Fluconazole</li><li>Metronidazole</li><li>Doxycycline</li></ol><button aria-controls=explanation-DUB aria-expanded=false class="btn btn-secondary" data-target=#explanation-DUB data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DUB><p class=correct-answer><strong>Answer:</strong> C</p>Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women of childbearing age.<br><br><span style="text-decoration: underline;">Typical symptoms of BV include the following:</span><br><br>1. Vaginal odor (the most common, and often initial, symptom of BV); often recognized only after sexual intercourse <br>2. Mildly to moderately increased vaginal discharge <br>3. Vulvar irritation (less common) <br>4. Dysuria or dyspareunia (rare)<br><br><span style="text-decoration: underline;">Risk factors that may predispose patients to BV include the following:</span><br>1. Recent antibiotic use <br>2. Decreased estrogen production of the host <br>3. Wearing an intrauterine device (IUD) <br>4. Douching <br>5. Sexual activity that could lead to transmission (eg, having a new sexual partner or a recent increase in the number of sexual partners) <br><br><span style="text-decoration: underline;">General principles of treatment of BV include the following:</span><br>1. Antibiotics are the mainstay of therapy <br>2. BV occurring in pregnant women should be treated<br>3. The treatment of choice for bacterial vaginosis in both pregnant and non pregnant patients is oral metronidazole.<br>4. Vaginal metronidazole and clindamycin are alternatives.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>53. </span> Which of the following complications are associated with smoking during pregnancy? </p><ol class=mt-3 type=A><li>Low birth weight</li><li>Uterine rupture</li><li>Gestational diabetes</li><li>Breech presentation</li></ol><button aria-controls=explanation-QS9 aria-expanded=false class="btn btn-secondary" data-target=#explanation-QS9 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-QS9><p class=correct-answer><strong>Answer:</strong> A</p>1. Cigarette smoking during pregnancy is the most important modifiable risk factor associated with adverse pregnancy outcomes.<br>2. In addition, smoking and secondhand smoke exposure increase the risk of infertility, placental abruption, preterm premature rupture of membranes (PPROM), and placenta previa.<br>3. Smoking during pregnancy is a well-established determinant of fetal growth and risk of low birthweight.<br>4. Maternal smoking in pregnancy may influence the development of the fetal respiratory system, as suggested by findings of a relation between maternal smoking in pregnancy and lung function impairment in newborns<br>5. Maternal smoking in pregnancy increases the risk of asthma during the first 7 years of life, and only a small fraction of the effect seems to be mediated through fetal growth.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>54. </span> Which of the following is the drug of choice for treating a patient with primary dysmenorrhea? </p><ol class=mt-3 type=A><li>IV estrogen</li><li>Levonorgestrol</li><li>Selective serotonin receptor inhibitors</li><li>Nonsteroidal anti-inflammatory drugs</li></ol><button aria-controls=explanation-2TW aria-expanded=false class="btn btn-secondary" data-target=#explanation-2TW data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-2TW><p class=correct-answer><strong>Answer:</strong> D</p>1. Dysmenorrhea is uterine pain around the time of menses. Pain may occur with menses or precede menses by 1 to 3 days. Pain tends to peak 24 h after onset of menses and subside after 2 to 3 days. It is usually sharp but may be cramping, throbbing, or a dull, constant ache; it may radiate to the legs.<br>2. Primary dysmenorrhea refers to recurrent, crampy lower abdominal pain, along with nausea, vomiting, and diarrhea, that occurs during menstruation in the absence of pelvic pathology. <br>3. Primary dysmenorrhea can be distinguished from secondary dysmenorrhea via normal physical examination.<br>4. Non-steroidal antiinflammatory drugs (NSAIDs, i.e., prostaglandin synthetase inhibitors) are the first choice in treatment.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>55. </span> Which of the following is the drug of choice for treating hyperthyroidism during the first trimester? </p><ol class=mt-3 type=A><li>Levothyroxine</li><li>Propylthiouracil</li><li>Propranolol</li><li>Radioactive iodine</li></ol><button aria-controls=explanation-W2K aria-expanded=false class="btn btn-secondary" data-target=#explanation-W2K data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-W2K><p class=correct-answer><strong>Answer:</strong> B</p>Hyperthyroidism can result from excess production of TSH (rare) or abnormal thyroid stimulators. <br>1. Thyroid disorders may predate or develop during pregnancy. Pregnancy does not change the symptoms of hypothyroidism and hyperthyroidism or the normal values and ranges of free serum thyroxine (T4) and thyroid-stimulating hormone (TSH).<br>2. Fetal effects vary with the disorder and the drugs used for treatment. But generally, untreated or inadequately treated hyperthyroidism can result in fetal growth restriction, preeclampsia, and stillbirth, and untreated hypothyroidism can cause intellectual deficits in offspring and miscarriage. The most common causes of maternal hypothyroidism are Hashimoto thyroiditis and treatment of Graves disease.<br>3. In the first trimester of pregnancy, the preferred drug to treat hyperthyroidism is propylthiouracil (PTU). Another antithyroid drug, methimazole, may cause birth defects if taken during early in pregnancy. Women may need to take methimazole in the first three months of pregnancy if they cannot tolerate PTU<br>4. Use of radioactive iodine is contraindicated in pregnancy.<br>5. Levothyroxine is used to treat thyroid hormone deficiency</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>56. </span> Which of the following is a frequent cause of female infertility? </p><ol class=mt-3 type=A><li>Diabetes mellitus</li><li>Smoking</li><li>Sexually Transmitted Infections</li><li>Endometriosis</li></ol><button aria-controls=explanation-Z7V aria-expanded=false class="btn btn-secondary" data-target=#explanation-Z7V data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-Z7V><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Infertility</strong></span> is the failure to conceive (regardless of cause) <span style="text-decoration: underline;">after 1 year of unprotected intercourse</span>. This condition affects approximately 10-15% of reproductive-aged couples.<br><br><span style="text-decoration: underline;"><strong>Female factors that affect fertility include the following categories:</strong></span><br>1. Cervical: Stenosis or abnormalities of the mucus-sperm interaction <br>2. Uterine: Congenital or acquired defects; may affect endometrium or myometrium; may be associated with primary infertility or with pregnancy wastage and premature delivery <br>3. Ovarian: Alteration in the frequency and duration of the menstrual cycle—Failure to ovulate is the most common infertility problem <br>4. Tubal: Abnormalities or damage to the fallopian tube; may be congenital or acquired <br>5. Peritoneal: Anatomic defects or physiologic dysfunctions (eg, infection, adhesions, adnexal masses) <br><br><span style="text-decoration: underline;"><strong>The most common identifiable female factors, which accounted for 81% of female infertility, were:</strong></span><br>1. Ovulatory disorders (25%)<br>2. Endometriosis (15%)<br>3. Pelvic adhesions (12%)<br>4. Tubal blockage (11%)<br>5. Other tubal abnormalities (11%)<br>6. Hyperprolactinemia (7%)</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>57. </span> What is the most common site of ectopic pregnancy? </p><ol class=mt-3 type=A><li>Isthmic tube</li><li>Ovary</li><li>Ampulla of the fallopian tube</li><li>Cervix</li></ol><button aria-controls=explanation-M9P aria-expanded=false class="btn btn-secondary" data-target=#explanation-M9P data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-M9P><p class=correct-answer><strong>Answer:</strong> C</p>1. Ectopic pregnancy is the result of a flaw in human reproductive physiology that allows the conceptus to implant and mature outside the endometrial cavity, which ultimately ends in the death of the fetus. <br>2. Without timely diagnosis and treatment, ectopic pregnancy can become a life-threatening situation.<br>3. An ectopic pregnancy is characterized by an adnexal mass and empty uterus on ultrasound. â€¨<br>4. The most likely site of an ectopic pregnancy is the ampulla. Cervical, ovarian, and abdominal ectopics are very rare<br><br>The classic clinical triad of ectopic pregnancy is as follows:<br>1. Abdominal pain <br>2. Amenorrhea <br>3. Vaginal bleeding<br><br>The presence of the following signs suggests a surgical emergency:<br>1. Abdominal rigidity <br>2. Involuntary guarding <br>3. Severe tenderness<br>4. Evidence of hypovolemic shock (eg, orthostatic blood pressure changes, tachycardia) <br><br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>58. </span> Which of the following medication is used to accelerate fetal lung maturity? </p><ol class=mt-3 type=A><li>Betamethasone</li><li>Propranolol</li><li>Indomethacin</li><li>Dexamethasone</li></ol><button aria-controls=explanation-6UY aria-expanded=false class="btn btn-secondary" data-target=#explanation-6UY data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-6UY><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>The most important complication of Preterm premature rupture of membranes (PPROM) is pulmonary hypoplasia (immaturity). </strong><br>2. <span style="text-decoration: underline;"><strong>Steroids</strong></span> are used to enhance fetal lung maturity when premature rupture of membranes occurs <strong>at less than 34-weeks of gestation.</strong> <br>3. In women at risk for preterm delivery, antenatal corticosteroids are frequently administered <strong>to prevent fetal lung immaturity at birth.</strong><br>4. Corticosteroids stimulate the synthesis and release of surfactants into the alveolar spaces.<br>5. Although all corticosteroids can affect this change if therapeutic concentrations reach the fetus, only betamethasone and, to a lesser extent, dexamethasone are routinely used for this purpose. <br><strong>6. Betamethasone is the preferred corticosteroid.</strong></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>59. </span> A 25-year-old female at 15 weeks is complaining of palpitations, anxiety, and heat intolerance. An ECG shows sinus tachycardia with a rate of 110 beats/minute. Which of the following is the treatment of choice during her pregnancy? </p><ol class=mt-3 type=A><li>Iodine</li><li>Propothiouracil</li><li>Radioactive iodine</li><li>Partial thyroidectomy</li></ol><button aria-controls=explanation-8O7 aria-expanded=false class="btn btn-secondary" data-target=#explanation-8O7 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-8O7><p class=correct-answer><strong>Answer:</strong> B</p>1. <strong>Hyperthyroidism</strong> is characterized by hypermetabolism and elevated serum levels of free thyroid hormones.<br>2. Many common symptoms of hyperthyroidism are similar to those of adrenergic excess, such as nervousness, palpitations, hyperactivity, increased sweating, heat hypersensitivity, fatigue, increased appetite, weight loss, insomnia, weakness, and frequent bowel movements (occasionally diarrhea). Hypomenorrhea may be present.<br>3. <strong>Signs</strong> may include warm, moist skin; tremor; tachycardia; widened pulse pressure and atrial fibrillation.<br>4. <strong>Diagnosis</strong> is clinical and with thyroid function tests. Treatment depends on cause.<br>5. Hyperthyroidism is often treated with antithyroid drugs in pregnancy.<br>6. <span style="text-decoration: underline;">Propylthiouracil is recommended to be used during the first trimester and switch to methimazole is recommended thereafter to reduce </span>risk<span style="text-decoration: underline;"> of hepatotoxicity</span>.<br>7. This patient is symptomatic and should be treated with PTU or methimazole. <br>8. A low-dose beta-blocker could also be used to control symptoms until the PTU is effective. <br>9. <span style="text-decoration: underline;">Radioactive iodine is not safe </span>in<span style="text-decoration: underline;"> pregnancy and is contraindicated</span>. <br>10. Iodine may cause goiter in the neonate.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>60. </span> Which of the following is true regarding postpartum hemorrhage? </p><ol class=mt-3 type=A><li>Loss of more than 500 mL of blood for vaginal delivery</li><li>Loss of 500 mL of blood for C-section</li><li>Loss of 2000 mL of blood for C-section</li><li>Loss of more than 1000 mL of blood for vaginal delivery</li></ol><button aria-controls=explanation-X1U aria-expanded=false class="btn btn-secondary" data-target=#explanation-X1U data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-X1U><p class=correct-answer><strong>Answer:</strong> A</p><span style="text-decoration: underline;"><strong>Postpartum hemorrhage</strong></span><br>1. Defined as a loss of &gt; 500 mL of blood for vaginal delivery or &gt; 1000 mL for C-section occurring before, during, or after delivery of the placenta. <br>2. <strong>Uterine atony</strong> is the most common cause of postpartum hemorrhage. <br>3. <strong>Complications</strong> include acute blood loss (potentially fatal), anemia due to chronic blood loss (predisposes to puerperal infection), and <strong>Sheehan’s syndrome</strong> (pituitary ischemia and necrosis; the 1° cause of anterior pituitary insufficiency in adult females, most commonly presenting as failure to lactate).</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>61. </span> A 29-year-old woman at 37 weeks is brought to the emergency room with sudden vaginal bleeding, severe uterine contractions and back pain. Her past medical history is significant for hypertension. Fetal heart tracing is nonreassuring. Examination shows uterine tenderness and hyperactivity.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Uterine rupture</li><li>Abruptio placenta</li><li>Vasa praevia</li><li>Threatened abortion</li></ol><button aria-controls=explanation-GF1 aria-expanded=false class="btn btn-secondary" data-target=#explanation-GF1 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-GF1><p class=correct-answer><strong>Answer:</strong> B</p><span style="text-decoration: underline;"><strong>Abruptio placentae</strong></span><br>1. Premature separation of the placenta from uterine wall leading to significant maternal hemorrhage <br>2. <strong>Risk factors</strong>: HTN, prior abruptio placentae, trauma, tobacco use, cocaine use, PROM, multiple gestation, multiparity <br>3. Classic features of acute abruptio placenta include:<span style="text-decoration: underline;"> Painful third trimester <strong>dark</strong> vaginal bleeding that does</span> not spontaneously cease, abdominal pain, uterine contractions and uterine tenderness. The absence of blood on pelvic examination does not rule out this condition.<br>4. <strong>Ultrasound</strong>: inconsistently shows separation of placenta from uterus (normal ultrasound is most likely)<br>5. <strong>Treatment</strong>  Bed rest in inpatient setting for very mild cases Delivery typically occurs rapidly secondary to uterine irritation, but caesarean section should be performed in cases of hemodynamic instability.<br>6. Transfusion is frequently required for significant hemorrhage. <br>7. <strong>Complications</strong>: DIC; severe hemorrhage that increases risk of maternal death.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>62. </span> A delivery before how many weeks of gestation is called the Preterm birth refers to a delivery? </p><ol class=mt-3 type=A><li>37</li><li>34</li><li>28</li><li>40</li></ol><button aria-controls=explanation-NAN aria-expanded=false class="btn btn-secondary" data-target=#explanation-NAN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-NAN><p class=correct-answer><strong>Answer:</strong> A</p>1. Labor (contractions resulting in cervical change) that begins before <strong>37 wk</strong> gestation is <strong><span style="text-decoration: underline;">considered preterm</span></strong>. <br>2. <strong>Risk factors</strong> include premature rupture of membranes, uterine abnormalities, infection, cervical incompetence, prior preterm birth, multifetal pregnancy, and placental abnormalities. <br>3. Diagnosis is clinical. <br>4. Causes are identified and treated if possible. <br>5. <strong>Management</strong> typically includes bed rest, tocolytics (if labor persists), corticosteroids (if gestational age is &lt; 34 wk), and possibly magnesium sulfate (if gestational age is &lt; 32 wk). <br>6. Antistreptococcal antibiotics are given pending negative anovaginal culture results.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>63. </span> Which of the following is the drug of choice for treatment of hyperthyroidism during pregnancy? </p><ol class=mt-3 type=A><li>Radioactive iodine</li><li>Methimazole</li><li>Propylthiouracil</li><li>Propranolol</li></ol><button aria-controls=explanation-V61 aria-expanded=false class="btn btn-secondary" data-target=#explanation-V61 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-V61><p class=correct-answer><strong>Answer:</strong> C</p>1. Hyperthyroidism during pregnancy is usually associated with Graves' disease.<br>2. Laboratory findings include an elevated triiodothyronine, thyroxine, and low sensitive thyroid-stimulating hormone. Treatment depends on the situation.<br>3. Antithyroid medications readily cross the placenta and inhibit fetal thyroid function. Propylthiouracil and methimazole cross the placenta but are used in the treatment of hyperthyroidism during pregnancy. <br>4. Propylthiouracil does not cross the placenta as easily as methimazole and is the drug of choice. Radioactive iodine ablation of the thyroid is contraindicated during pregnancy.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>64. </span> Which of the following is the most common cause of galactorrhea? </p><ol class=mt-3 type=A><li>Hyperprolactinemia</li><li>Nipple stimulation</li><li>Hypothyroidism</li><li>Psychotropic medication</li></ol><button aria-controls=explanation-V5D aria-expanded=false class="btn btn-secondary" data-target=#explanation-V5D data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-V5D><p class=correct-answer><strong>Answer:</strong> A</p>Galactorrhea is defined as lactation in men or non-breastfeeding women; it may be a sign of a potentially significant disorder and should be evaluated <br><br>Physiologic galactorrhea is usually bilateral and guaiac negative (as in this patient); the appearance is typically milky or clear but can also be yellow, brown, gray, or green. This patient has bilateral, guaiac-negative discharge without signs of malignancy (eg, breast mass, lymphadenopathy, nipple changes, unilateral discharge). Initial evaluation should focus on Identifying the etiology and includes serum prolactin, TSH, and a pregnancy test. <br><br>Hyperprolactinemia Is the most common cause of galactorrhea and can be due to pituitary prolactinoma, medications, hypothyroidism, pregnancy, or chest wall/nipple stimulation(eg, surgery.trauma, shingles). <br>Pituitary imaging (usually MRI) may be needed in patients with elevated prolactin and/or symptoms of a pituitary mass (eg, vision disturbances, headaches).</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>65. </span> Which of the following is the treatment of choice for an infertile women with polycystic ovary syndrome ? </p><ol class=mt-3 type=A><li>Metformin</li><li>Clomiphene citrate</li><li>Spironolactone</li><li>Eflornithine</li></ol><button aria-controls=explanation-BGW aria-expanded=false class="btn btn-secondary" data-target=#explanation-BGW data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-BGW><p class=correct-answer><strong>Answer:</strong> B</p>1. <strong>Polycystic ovary syndrome</strong> (PCOS) is the most common cause of infertility in women.<br>2. The clinical triad of polycystic ovarian disease (PCOD) is <span style="text-decoration: underline;"><strong>amenorrhea</strong></span>, <span style="text-decoration: underline;"><strong>hirsutism</strong></span> and <span style="text-decoration: underline;"><strong>obesity</strong></span>. <br>3. It is characterized by anovulation, signs of androgen excess and ovarian cysts. <br>4. Examinations usually reveals <span style="text-decoration: underline;"><strong>hirsutism</strong></span>, <span style="text-decoration: underline;"><strong>obesity</strong></span>, <span style="text-decoration: underline;"><strong>male pattern baldness</strong></span> and <span style="text-decoration: underline;"><strong>increased acne</strong></span>.<br><strong>5. Clomiphene citrate or human menopausal gonadotropin (HMG) is the treatment of choice for infertility.</strong><br>6.<strong>Metformin</strong> is indicated in polycystic ovarian syndrome patients with impaired glucose tolerance. It helps in preventing type 2 diabetes mellitus.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>66. </span> Which of the following is an absolute contraindication for IUD placement ? </p><ol class=mt-3 type=A><li>Endometriosis</li><li>History of an ectopic pregnancy</li><li>History of deep venous thrombosis</li><li>Ongoing pelvic infection</li></ol><button aria-controls=explanation-O5N aria-expanded=false class="btn btn-secondary" data-target=#explanation-O5N data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-O5N><p class=correct-answer><strong>Answer:</strong> D</p>Intrauterine contraception (IUD) is the most commonly used method of long-acting reversible contraception because of its high efficacy and safety, ease of use, and low cost.<br><br>There are 2 main types of IUDs: <br>1. Copper <br>2. Levonorgestrel  <br><br><strong>Complications</strong> from IUD placement are relatively rare. The most common complication is IUD expulsion.<br>Pregnancy with an IUD in situ increases risk for miscarriage, ectopic pregnancy, &amp; premature birth. <br><br><strong>IUD use is contraindicated:</strong><br><br>1. Absolute contraindications for IUD use include the following:<br>2. Pregnancy <br>3. Significantly distorted uterine anatomy (e.g. fibroids, congenital or acquired uterine abnormality) <br>4. Cervical, endometrial or ovarian cancer awaiting treatment <br>5. Unexplained vaginal bleeding concerning for pregnancy or pelvic malignancy <br>6. Gestational trophoblastic disease with persistently elevated beta-human chorionic gonadotropin levels <br>7. Ongoing pelvic infection (eg, pelvic inflammatory disease, untreated cervicitis, puerperal sepsis, immediate postabortion or postpartum infection, endomyometritis, pelvic tuberculosis)<br><br><br><strong>IUD use is safe:</strong><br><br>1. History of pelvic surgery <br>2. History of deep venous thrombosis <br>3. History of an ectopic pregnancy <br>4. History of migraine headaches <br>5. Hypertension or any heart disease <br>6. Diabetes<br>7. Anemia <br>8. Endometriosis<br>9. Smoking</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>67. </span> Which of the following is is trug regarding lab tests during pregnancy? </p><ol class=mt-3 type=A><li>Increased white blood cell count</li><li>Increased hemoglobin</li><li>Decreased lactic dehydrogenase</li><li>Decreased alkaline phosphatase</li></ol><button aria-controls=explanation-DS9 aria-expanded=false class="btn btn-secondary" data-target=#explanation-DS9 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DS9><p class=correct-answer><strong>Answer:</strong> A</p>Many laboratory values are affected during pregnancy:<br>1. Hemoglobin/hematocrit: decreased<br>2. White blood cell count: increased<br>3. Fibrinogen level: increased<br>4. Erythrocyte sedimentation rate: increased<br>5. Albumin level: decreased<br>6. Fasting blood glucose: decreased<br>7. Lactic dehydrogenase: increased<br>8. Creatinine phosphokinase: increased<br>9. Alkaline phosphatase: increased<br>10. Calcium (total): decreased<br>11. Cortisol: increased<br>12. Prolactin: increased<br>13. Thyroxine total: increased</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>68. </span> A 25-year-old woman comes to the doctor with vaginal discharge and vulvar pruritus. Examination shows a thin, malodorous green vaginal discharge.<br><br>Which of the following is the treatment of choice for this patient? </p><ol class=mt-3 type=A><li>Azithromycin for the patient and her sexual partner.</li><li>Oral metronidazole for the patient.</li><li>Oral metronidazole for the patient and her sexual partner.</li><li>Fluconazole for the patient only.</li></ol><button aria-controls=explanation-KLO aria-expanded=false class="btn btn-secondary" data-target=#explanation-KLO data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-KLO><p class=correct-answer><strong>Answer:</strong> C</p><span style="text-decoration: underline;"><strong>Trichomonas vaginalis</strong></span><br><strong>Transmission</strong> :Sexual (cannot exist outside human because it cannot form cysts) <br><strong>Treatment</strong>: Metronidazole for patient and partner (prophylaxis)<br><br> <table class="table table-responsive table-sm table-striped"> <tbody> <tr> <td><strong>Characteristics</strong></td> <td><strong>Gardnerella vaginalis</strong></td> <td><strong>Trichomonas vaginalis</strong></td> <td><strong>Candida albicans</strong></td> </tr> <tr> <td><span style="text-decoration: underline;">Physical examination</span></td> <td>Mild vaginal inflammation</td> <td>Vaginal and cervical inflammation, cervical petechiae</td> <td>Significant vaginal inflammation</td> </tr> <tr> <td><span style="text-decoration: underline;">Discharge</span></td> <td>Thin, white, fishy odor</td> <td>Malodorous, frothy, greenish</td> <td>Thick, white, “cottage cheese–like”</td> </tr> <tr> <td><span style="text-decoration: underline;">Wet mount (saline)</span></td> <td>Clue cells</td> <td>Motile trichomonads</td> <td>Normal</td> </tr> <tr> <td><span style="text-decoration: underline;">Wet mount (KOH)</span></td> <td>Fishy odor</td> <td>Possible fishy odor</td> <td>Pseudohyphae</td> </tr> <tr> <td><span style="text-decoration: underline;">Vaginal pH</span></td> <td>4.5 (high)</td> <td>4.5 (high)</td> <td>3.5–4.5 (normal)</td> </tr> <tr> <td><span style="text-decoration: underline;">Treatment</span></td> <td>Metronidazole</td> <td>Metronidazole (also treat partner)</td> <td>Topical clotrimazole, miconazole, or nystatin, or oral fluconazole (single dose(</td> </tr> </tbody> </table></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>69. </span> Which of the following is the most common effect of smoking during pregnancy on newborn? </p><ol class=mt-3 type=A><li>Infantile spasms</li><li>Hypoglycemia</li><li>Neural tube defect</li><li>Low birth weight</li></ol><button aria-controls=explanation-NKJ aria-expanded=false class="btn btn-secondary" data-target=#explanation-NKJ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-NKJ><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Smoking during pregnancy</strong> carries the risk of preterm birth. Smoking during pregnancy is associated with smaller, premature newborns, but not with tachypnea, specific birth defects, hypoglycemia, or macrosomia. <br><strong>2. The most common effect of smoking during pregnancy is a reduction in birth weight.</strong></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>70. </span> What is the definition of menometrorrhagia? </p><ol class=mt-3 type=A><li>Excessive bleeding at usual time of menstrual periods and at other irregular intervals</li><li>Total cessation of the menstrual period</li><li>Bleeding that is decreased in amount</li><li>Bleeding at regular intervals that is prolonged in duration (&gt;7 d) or excessive in amount</li></ol><button aria-controls=explanation-ZAZ aria-expanded=false class="btn btn-secondary" data-target=#explanation-ZAZ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ZAZ><p class=correct-answer><strong>Answer:</strong> A</p><span style="text-decoration: underline;">Abnormal Uterine Bleeding</span><br>1-<strong>Hypomenorrhea</strong>: bleeding that is decreased in amount<br>2-<strong>Oligomenorrhea</strong>: bleeding occurring at intervals &gt;35 d<br>3-<strong>Polymenorrhea</strong>: bleeding occurring at intervals  Menorrhagia/hypermenorrhea: bleeding at regular intervals that is prolonged in duration (&gt;7 d) or excessive in amount (&gt;80 cc per menstrual cycle)<br>4-<strong>Metrorrhagia</strong>: bleeding at irregular intervals, particularly between expected menstrual periods<br>5-<strong>Menometrorrhagia</strong>: excessive bleeding at usual time of menstrual periods and at other irregular intervals<br>6-<strong>Postmenopausal bleeding</strong>: any bleeding that presents &gt;1 yr after menopause; must rule out endometrial cancer<br>7-<strong>Amenorrhea</strong> : total cessation of the menstrual period</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>71. </span> Which of the following lab results is suggestive of menopause? </p><ol class=mt-3 type=A><li>High serum FSH</li><li>Hyperglycemia</li><li>Low serum LH</li><li>Hypocalcemia</li></ol><button aria-controls=explanation-MI7 aria-expanded=false class="btn btn-secondary" data-target=#explanation-MI7 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-MI7><p class=correct-answer><strong>Answer:</strong> A</p>1. Natural menopause is defined as the permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of amenorrhea without any other obvious pathological or physiological cause.<br>2. It occurs at a median age of <strong>51.4 years in normal women</strong>.<br>3. Menopause<span style="text-decoration: underline;"> before age 40</span> is <strong>considered to be abnormal</strong> and is referred to as primary ovarian insufficiency (premature ovarian failure).<br>4. <span style="text-decoration: underline;"><strong>Symptoms</strong></span> of menopause include irregular or absent menses, heat intolerance, flushing, insomnia, and night sweats. <br>5. <strong>Hot flashes is the most common symptom during the menopausal transition.</strong><br>6. Menopause results in <strong>increased LDL</strong>,<strong> decreased HDL</strong>, <strong>osteoporosis</strong>, and <strong>high risk of heart disease</strong> due to lack of effect of estrogen on cholesterol balance, and also due to altered vascular endothelium reactivity due to decreased estrogen. <br>7. In menopause, the circulating estrogen decreases, resulting in decrease in the feedback inhibition on the hypothalamic-pituitary axis, resulting in <strong>elevation of serum FSH and LH levels</strong>.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>72. </span> A 47-year-old woman presents to your office with heavy bleeding. She is a nonsmoker. Which of the following is the treatment of choice for dysfunctional uterine bleeding? </p><ol class=mt-3 type=A><li>Oral contraceptive pill</li><li>Hysterectomy</li><li>Reassurance</li><li>Dilation and curettage</li></ol><button aria-controls=explanation-ZMZ aria-expanded=false class="btn btn-secondary" data-target=#explanation-ZMZ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ZMZ><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Dysfunctional uterine bleeding</strong> (DUB) refers to heavy vaginal bleeding that occurs in the absence of structural or organic disease.<br>2. After menarche and before menopause it is considered physiologic.<br>3. DUB is the most common cause of abnormal uterine bleeding.<br>4. Due to its benign nature, it is a diagnosis of exclusion.<br>5. The most common cause of dysfunctional uterine bleeding (DUB) in adolescent women is anovulation.<br>6. DUB is treated with cyclic progestin therapy from day 14 – 25 of each cycle or by daily combination OCPs.<br>7. Cases not controlled by hormonal therapy may undergo endometrial ablation or hysterectomy.<br>8. In cases of uncontrolled bleeding, IV estrogen is the drug of choice for, to suppress the bleeding, and to ensure cardiovascular stability.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>73. </span> A 20-year-old primigravid woman is unable to lactate her baby. Her delivery was complicated by vaginal bleeding that required blood transfusion. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Sheehan syndrome</li><li>Subarachnoidal hemorrhage</li><li>Berry aneurysm</li><li>Spetic shock</li></ol><button aria-controls=explanation-1IW aria-expanded=false class="btn btn-secondary" data-target=#explanation-1IW data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-1IW><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Sheehan syndrome</strong> is a rare cause of pituitary apoplexy and hypopituitarism.<br>2. It only occurs in postpartum females who experience large volume haemorrhage and hypovolaemic shock, either during delivery or afterwards.<br>3. The two most common causes of hypopituitarism in the postpartum period are Sheehan's syndrome and lymphocytic hypophysitis. <br>4. Patients with Sheehan's syndrome present in the postpartum period with failure to lactate and other features of pituitary hormonal deficiency. <br>5. Failure to lactate or difficulties with lactation are common <span style="text-decoration: underline;">initial symptoms</span> of Sheehan syndrome.<br>6. Pathophysiology: hypovolaemia secondary to postpartum haemorrhage leads to pituitary infarction and necrosis.<br><br><span style="text-decoration: underline;">Clinical presentation<br></span><br>Pituitary failure <br>1. may be silent and present with delayed hypopituitarism<br>2. amenorrhoea<br>3. adrenal insufficiency<br>4. hypothyroidism<br>5. adrenal insufficiency<br>6. hyponatraemia<br>7. growth hormone deficiency<br><br>Optic chiasm compression<br>1. visual field loss<br>2. headache<br>3. ophthalmoplegia</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>74. </span> Which of the following is the treatment of choice for candida vaginitis? </p><ol class=mt-3 type=A><li>Amoxicillin</li><li>Doxycycline</li><li>Fluconazole</li><li>Oral nystatin</li></ol><button aria-controls=explanation-5A8 aria-expanded=false class="btn btn-secondary" data-target=#explanation-5A8 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-5A8><p class=correct-answer><strong>Answer:</strong> C</p>1. Candida vaginitis is not considered a sexually transmitted disease and occurs in presence of risk factors <br>2. such as diabetes mellitus, oral contraceptive pills, pregnancy and immunosuppressive therapy.<br>3. Pseudohyphae are characteristically seen on wet mount preparations of vaginal discharge from patients with candida vulvovaginitis.<br>4. Symptomatic patients are treated with an azole antifungal e.g fluconazole.<br>5. Sexual partner do not require treatment.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>75. </span> A 28-year-old woman presents to the physician with a rubbery, firm, mobile and painful mass in her left breast. She had severe pain in this mass during her menses. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Breast cancer</li><li>Fibrocystic Breast Disease</li><li>Fibroadenoma</li><li>Fat necrosis</li></ol><button aria-controls=explanation-6BC aria-expanded=false class="btn btn-secondary" data-target=#explanation-6BC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-6BC><p class=correct-answer><strong>Answer:</strong> B</p>Fibrocystic Breast Disease<br><br>1. <span style="text-decoration: underline;"><strong>Definition</strong></span>: Changes in the breast that occur due to evolution and involution.<br>2. It is benign condition. <br>3. Very common in pre-menopausal females.<br>4. Patients present with bilateral painful, rubbery, firm, mobile masses; who experiences more tenderness during her menses.<br>5. <span style="text-decoration: underline;"><strong>Exam</strong></span>: Nodular breast diffusely on palpation.<br>6. <span style="text-decoration: underline;"><strong>Diagnosis</strong></span>: Excisional biopsy is the gold standard.<br>7. <span style="text-decoration: underline;"><strong>Complication</strong></span>: Breast cancer.<br>8. <span style="text-decoration: underline;"><strong>Treatment</strong></span>: Supportive, except for large lesions, e.g., Cysts or lumps, which can be excised. <br>9. Fibrocystic disease is treated with aspiration of the cyst, which should yield clear fluid (serous “greenish” and non-bloody) and result in the disappearance of the mass. Afterwards, patients are typically observed for 4 to 6 weeks.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>76. </span> Which of the following antihypertensive is contraindicated in pregnancy? </p><ol class=mt-3 type=A><li>Methyldopa</li><li>Hydralazine</li><li>Nifedipine</li><li>Captopril</li></ol><button aria-controls=explanation-ALA aria-expanded=false class="btn btn-secondary" data-target=#explanation-ALA data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ALA><p class=correct-answer><strong>Answer:</strong> D</p><img alt class=img-fluid height=190 src=data:image/png;base64,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 width=490></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>77. </span> An 18-year-old woman presents to with pelvic pain, dysuria, and a purulent yellowish-green vaginal discharge. A Gram's stain of cervical secretions shows gram-negative diplococci. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Trichomoniasis</li><li>Endometritis</li><li>Chlamydia</li><li>Gonorrhea</li></ol><button aria-controls=explanation-R62 aria-expanded=false class="btn btn-secondary" data-target=#explanation-R62 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-R62><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Gonorrhea</strong> is caused by the bacteria Neisseria gonorrhoeae.<br>2. It typically infects epithelia of the urethra, cervix, rectum, pharynx, or conjunctivae, causing irritation or pain and purulent discharge.<br>3. Dissemination to skin and joints, which is uncommon, causes sores on the skin, fever, and migratory polyarthritis or pauciarticular septic arthritis. <br>4. Diagnosis is by microscopy, culture, or nucleic acid amplification tests.<br>5. Gram stain is sensitive and specific for gonorrhea in men with urethral discharge; gram-negative intracellular diplococci typically are seen. Gram stain is much less accurate for infections of the cervix, pharynx, and rectum and is not recommended for diagnosis at these sites.<br>6. Several oral or injectable antibiotics can be used, but drug resistance is an increasing problem.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>78. </span> Which of the following is the most common cause of postpartum hemorrhage? </p><ol class=mt-3 type=A><li>Hematoma</li><li>Bleeding disorders</li><li>Uterine rupture</li><li>Uterine atony</li></ol><button aria-controls=explanation-PLS aria-expanded=false class="btn btn-secondary" data-target=#explanation-PLS data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-PLS><p class=correct-answer><strong>Answer:</strong> D</p>Postpartum hemorrhage is blood loss of &gt; 500 mL during or immediately after the 3rd stage of labor in a vaginal delivery or &gt; 1000 mL in a cesarean delivery.<br><br>Causes of postpartum hemorrhage include:<br>1. Uterine atony (The most common cause of postpartum hemorrhage)<br>2. Lacerations of the genital tract<br>3. Extension of an episiotomy<br>4. Uterine rupture<br>5. Bleeding disorders<br>6. Retained placental tissues<br>7. Hematoma<br>8. Uterine inversion<br>9. Chorioamnionitis<br><br>Treatment depends on etiology of the hemorrhage.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>79. </span> A 30-year-old woman presents to the physician with a grayish, foul-smelling discharge. A saline wet mount examination reveals numerous epithelial cells coated with bacteria.<br><br>Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Trichomoniasis</li><li>Yeast infection</li><li>Chlamydia</li><li>Bacterial vaginosis</li></ol><button aria-controls=explanation-6C7 aria-expanded=false class="btn btn-secondary" data-target=#explanation-6C7 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-6C7><p class=correct-answer><strong>Answer:</strong> D</p>1.<span style="text-decoration: underline;"><strong> Bacterial vaginosis</strong></span> typically presents with minimal to absent vaginal inflammation and a discharge (pH &gt;4.5) that is thin, off-white in color, and has a "fishy" odor.<br>2. Thin, gray-white vaginal discharge<br>3. "<strong>Clue cells"</strong> (vaginal epithelial cells with adherent coccobacilli) on wet mount<br>4. The treatment of choice for Bacterial Vaginosis in a pregnant lady is clindamycin cream (not orally) or metronidazole cream.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>80. </span> Which of the following is the most common factor responsible for a couple's infertility? </p><ol class=mt-3 type=A><li>Male factor</li><li>Tubal and peritoneal factor</li><li>Uterine factor</li><li>Ovulatory factor</li></ol><button aria-controls=explanation-QWR aria-expanded=false class="btn btn-secondary" data-target=#explanation-QWR data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-QWR><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Infertility</strong> is usually defined as inability of a couple to conceive after 1 yr of unprotected intercourse.<br>2. The most common cause of infertility is male factors.<br>3. Infertility can be caused by the following: <br>4. Sperm disorders (≥ 35% of couples)<br>5. Ovulatory dysfunction or decreased ovarian reserve (about 20%)<br>6. Tubal dysfunction and pelvic lesions (about 30%)<br>7. Abnormal cervical mucus (≤ 5%)<br>8. Unidentified factors (about 10%)</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>81. </span> Which of the following is the most appropriate management of postpartum hemorrhage?<br><br> </p><ol class=mt-3 type=A><li>Oxytocin infusion</li><li>Dilatation and curettage</li><li>Uterine artery embolization</li><li>Hysterectomy</li></ol><button aria-controls=explanation-AFP aria-expanded=false class="btn btn-secondary" data-target=#explanation-AFP data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-AFP><p class=correct-answer><strong>Answer:</strong> A</p>1. Postpartum hemorrhage (PPH) is an obstetrical emergency. It is a major cause of maternal morbidity.<br>2. Postpartum Hemorrhage is defined as blood loss of more than 500 mL following vaginal delivery or more than 1000 mL following cesarean delivery. <br>3. Uterine atony is the most common cause of postpartum hemorrhage. <br><br>Treatment:<br>1. Treatment depends on etiology of the hemorrhage.<br>2. Uterine massage; if that fails, give oxytocin. <br>3. If hemorrhage persists, consider packing, surgical procedures, and transfusion of blood products.<br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>82. </span> Which of the following is the gold standard for the diagnosis of endometriosis? </p><ol class=mt-3 type=A><li>CT of the pelvis</li><li>Pap smear</li><li>Laparoscopy</li><li>Ultrasound</li></ol><button aria-controls=explanation-YJL aria-expanded=false class="btn btn-secondary" data-target=#explanation-YJL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-YJL><p class=correct-answer><strong>Answer:</strong> C</p>1. Patients with <span style="text-decoration: underline;"><strong>endometriosis</strong></span> present with dysmenorrhea, dyspareunia and dyschezia and the physical exam reveals tender adnexal mass and firm nodularity located in the broad ligaments, the uterosacral ligament or in the cul-de-sac.<br>2. Ovaries is the most common site. <br>3. Endometriosis is the most common cause of female infertility. <br>4. U/S of the pelvis is suggestive, but diagnosis is confirmed only by visualizing the powder burn implants and chocolate cysts during laparoscopy. <br>5. <strong>Laparoscopy</strong> is the gold standard for the diagnosis of endometriosis.  <br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>83. </span> All the following are normal physiological changes in pregnancy except: </p><ol class=mt-3 type=A><li>Increase of Cardiac output &amp; heart rate</li><li>Decrease of gastric motility</li><li>Increase of Blood volume</li><li>Decrease of respiratory rate</li></ol><button aria-controls=explanation-IGN aria-expanded=false class="btn btn-secondary" data-target=#explanation-IGN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-IGN><p class=correct-answer><strong>Answer:</strong> D</p><br><img alt class=img-fluid height=312 src=data:image/jpeg;base64,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 width=380></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>84. </span> Which of the following is the treatment of choice for atrophic vaginitis ? </p><ol class=mt-3 type=A><li>Estrogen</li><li>Ciprofloxacin</li><li>Metronidazole</li><li>Corticosteroid cream</li></ol><button aria-controls=explanation-DMN aria-expanded=false class="btn btn-secondary" data-target=#explanation-DMN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DMN><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Menopause</strong> is the result of permanent loss of estrogen. Menopause occurs in patients aged 48 to 52. <br>2. Symptoms of menopause include irregular or absent menses, heat intolerance, flushing, insomnia, dyspareunia and night sweats. <br>3. <strong>Vaginal atrophy (atrophic vaginitis)</strong> is characterized by dryness, inflammation, and thinning of the epithelial lining of the vagina and lower urinary tract due to loss of estrogen.<br>4. <span style="text-decoration: underline;"><strong>Vaginal atrophy presents</strong></span> with vaginal dryness and dysuria, and physical exam findings of pale, dry vaginal mucosa, diminished labial fat pad, and scarce pubic hair. <br>5. It typically occurs in <span style="text-decoration: underline;"><strong>menopausal women</strong></span>.<br><strong>6. Atrophic vaginitis is treated with estrogen</strong></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>85. </span> A 35 year-old woman was seen in the Gynaecological Outpatient Clinic with excessive and offensive vaginal discharge.<br>What organism is the most likely cause of her vaginal discharge? </p><ol class=mt-3 type=A><li>Trichomonous vaginalis</li><li>Staphylococcus aureus</li><li>Gonococcal infection</li><li>Chlamydia trachomitis</li></ol><button aria-controls=explanation-LP9 aria-expanded=false class="btn btn-secondary" data-target=#explanation-LP9 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-LP9><p class=correct-answer><strong>Answer:</strong> A</p>1. <strong>Trichomoniasis</strong> is infection of the vagina or male genital tract with <span style="text-decoration: underline;">Trichomonas </span>vaginalis (TV).<br>2. TV is a flagellated protozoan. It is a sexually transmitted infection which usually causes an offensive vaginal discharge. <br>3. It can be asymptomatic or cause urethritis, vaginitis, or occasionally cystitis, epididymitis, or prostatitis.<br>4. Diagnosis is by direct microscopic examination, dipstick tests, or nucleic acid amplification tests of vaginal secretions or by urine or urethral culture. <br>5. Patients and sex partners are treated with metronidazole or tinidazole.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>86. </span> A 17-year-old girl is complaining of pain in her left breast for 3 months. On exam, you palpate two small 1-cm round rubbery masses in the right lower quadrant of her left breast. The masses are tender and noncompressible. No nodes are palpated in either axilla. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Fibrocystic change</li><li>Carcinoma of the breast</li><li>Cyst</li><li>Fibroadenoma</li></ol><button aria-controls=explanation-03X aria-expanded=false class="btn btn-secondary" data-target=#explanation-03X data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-03X><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Fibroadenoma</strong> classically presents as a discrete, firm, nontender, and highly mobile breast nodule.<br>2. The most common adolescent breast disorder is breast mass, the majority of which are fibroadenomas or benign cysts.<br>3. A clue to the diagnosis is a mass that’s highly mobile on clinical exam. <br>4. Fibroadenomas are made up of stromal and epithelial cells. <br>5. No treatment is necessary. Surgical removal can be done if the mass is growing.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>87. </span> Which of the following is an absolute contraindication to external cephalic version ? </p><ol class=mt-3 type=A><li>Scarred uterus</li><li>Ruptured membranes</li><li>Breech presentation</li><li>Oligohydramnios</li></ol><button aria-controls=explanation-LFI aria-expanded=false class="btn btn-secondary" data-target=#explanation-LFI data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-LFI><p class=correct-answer><strong>Answer:</strong> B</p>There are two types of contraindications :<br><br> <strong>Relative contraindication</strong> means that caution should be used when two drugs or procedures are used together. (It is acceptable to do so if the benefits outweigh the risk.)<br><br> <strong>Absolute contraindication</strong> it means that event or substance could cause a life-threatening situation thus it <span style="text-decoration: underline;">should be avoided.<br><br></span><strong>External cephalic version</strong> is a procedure in which the fetus is rotated from the breech to the cephalic presentation by manipulation through the mother's abdomen.<br><br>ECV is indicated if breech presentation is persistent after 37 weeks.<br>If ECV fails, then do cesarean delivery.<br><br><strong>Absolute Contraindications<br></strong><br>1. If caesarean section is indicated, e.g. placenta previa, previous Classical Caesarean section. <br>2. Abnormal cardiotocography;fetal heart rate abnormalities <br>3. Ruptured membranes <br>4. Contracted pelvis  <br>5. Fetal death  <br>6. Placental abruption <br><br> <strong>Relative contraindication  <br></strong><br>1. Small-for-gestational-age fetus with abnormal Doppler parameters; Fetal hypoxia <br>2. Pre-eclampsia with proteinuria; or Antepartum haemorrhage in the last week <br>3. Major fetal anomalies; Unstable lie; Multiple pregnancy <br>4. A restrictive nuchal cord, Hyper-extended head<br>5. Major uterine anomaly ; Scarred uterus <br>6. Oligohydramnios or hydramnios <span style="text-decoration: underline;"><br></span></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>88. </span> Which of the following is an absolute contraindication to the use of oral contraceptive pills?Which of the following is an absolute contraindication to the use of oral contraceptive pills? </p><ol class=mt-3 type=A><li>History of thrombophlebitis</li><li>History of Hypertension</li><li>Obesity</li><li>History of diabetes mellitus</li></ol><button aria-controls=explanation-JKD aria-expanded=false class="btn btn-secondary" data-target=#explanation-JKD data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-JKD><p class=correct-answer><strong>Answer:</strong> A</p><span style="text-decoration: underline;"><strong>The FDA's absolute contraindications to oral contraceptives:</strong></span><br>1. Deep vein thrombosis (current or history)<br>2. Pulmonary embolism (current or history)<br>3. Ischemic heart disease (current or history)<br>4. History of cerebrovascular accidents<br>5. Valvular heart disease with complications<br>6. Severe hypertension<br>7. Diabetes with vascular involvement<br>8. Headaches with focal neurological symptoms<br>9. Major surgery with prolonged immobilization<br>10. Known or suspected carcinoma of the breast or personal history of breast cancer<br>11. Liver tumors (benign and malignant), active liver disease<br>12. Known or suspected pregnancy<br>13. Heavy smoking (&gt;=15 cigarettes per day) and over age 35.<br><br>Among the relative contraindications are hypertension, surgeries that require a period of immobilization, major injury to the lower extremity, migraines, tobacco use, diabetes mellitus, sickle cell disease, major depression, gallbladder disease, hepatitis, and age older than 40 years if there is an additional risk such as for coronary artery disease.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>89. </span> Which of the following is the most common cause of secondary amenorrhea? </p><ol class=mt-3 type=A><li>Polycystic Ovary Syndrome</li><li>Cushing syndrome</li><li>Hypothyroidism</li><li>Pregnancy</li></ol><button aria-controls=explanation-DYD aria-expanded=false class="btn btn-secondary" data-target=#explanation-DYD data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DYD><p class=correct-answer><strong>Answer:</strong> D</p>1. <span style="text-decoration: underline;"><strong>Amenorrhea</strong></span> (absence of menses) can be a transient, intermittent, or permanent condition resulting from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina.<br>2. It is often classified as either <span style="text-decoration: underline;"><strong>primary</strong></span> (absence of menarche by age 15 years) or <span style="text-decoration: underline;"><strong>secondary</strong></span> (absence of menses for more than three cycles or six months in women who previously had menses).<br>3. Most common cause of primary amenorrhea: Ovarian, followed by uterine. <br><strong>4. Pregnancy is the most common cause of secondary amenorrhea.</strong><br>5. Most common cause of postpartum amenorrhea: <strong>Lactation</strong>.  <br><br><span style="text-decoration: underline;"><strong>The most common causes of secondary amenorrhea are disorders of the:</strong></span><br>1. Ovary — 40%<br>2. Hypothalamus — 35%<br>3. Pituitary — 19%<br>4. Uterus — 5%</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>90. </span> A 25-year-old primigravid woman at 28 weeks gestation is brought the doctor with high fever, dysuria, flank pain, nausea and vomiting. Which of the following is the most appropriate next step in management? </p><ol class=mt-3 type=A><li>Nitrofurantoin for 3 days</li><li>Oral antibiotics for 5 days</li><li>Surgical consultation</li><li>Hospitalization with administration of IV fluids and antibiotics</li></ol><button aria-controls=explanation-OBE aria-expanded=false class="btn btn-secondary" data-target=#explanation-OBE data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-OBE><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Pyelonephritis</strong></span> <br>1. Escherichia coli accounts for more than 70% of cases.<br>2. In pregnant patients, asymptomatic bacteruiria increases the risk of developing cystitis and pyelonephritis more than in the non-pregnant state.<br>3. Asymptomatic bacteruiria is a positive urine culture in the absence of urinary tract symptoms. <br>4. <strong>Clinical features</strong>: flank pain, chills, nausea, vomiting, urinary frequency, dysuria, urgency; fever (38°C), costovertebral tenderness<br>5. Recommended antibiotics in pregnancy are ampicillin, nitrofurantoin, or first generation oral cephalosporins. 6.Hospitalization is required if the patient has a high fever, dehydration, or other complicating medical conditions (e.g., pregnancy, diabetes). <br>7.Duration of antibiotic therapy depends on clinical response but should be at least 10 to 14 days. Intravenous antibiotics should be continued until the patient is afebrile.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>91. </span> A 33-year-old woman with a history of Pelvic inflammatory disease comes to the office for evaluation of infertility. Which of the following tests is used to identify the structural abnormalities for this patient? </p><ol class=mt-3 type=A><li>Hysteroscopy</li><li>Endometrial biopsy</li><li>Hysterosalpingogram</li><li>Loop Electrosurgical Excision Procedure (LEEP)</li></ol><button aria-controls=explanation-WR3 aria-expanded=false class="btn btn-secondary" data-target=#explanation-WR3 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-WR3><p class=correct-answer><strong>Answer:</strong> C</p>1. Infertility is usually defined as inability of a couple to conceive after 1 yr of unprotected Intercourse.<br>2. Hysterosalpingography (HSG) is a radiographic diagnostic study of the uterus and fallopian tubes most commonly used in the evaluation of infertility.<br>3. Identifying risk factors for tubal disease (e.g., pelvic inflammatory disease) is important when evaluating patients with infertility. <br><br>Infertility can be caused by the following:<br>1. Sperm disorders (≥ 35% )<br>2. Decreased ovarian reserve or ovulatory dysfunction (20%)<br>3. Tubal dysfunction and pelvic lesions (30%)<br>4. Abnormal cervical mucus (≤ 5%)<br>5. Unidentified factors (10%) <br><br>Pelvic inflammatory disease (PID)<br>1. PID is infection of the upper female genital tract: the cervix, uterus, fallopian tubes, and ovaries; abscesses may occur.<br>2. Common symptoms and signs include lower abdominal pain, cervical discharge, and irregular vaginal bleeding.<br>3. Long-term complications include infertility, chronic pelvic pain, and ectopic pregnancy.<br>4. Diagnosis includes PCR of cervical specimens for Neisseria gonorrhoeae and chlamydiae, microscopic examination of cervical discharge (usually), and ultrasonography or laparoscopy (occasionally).<br>5. Treatment is with antibiotics.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>92. </span> Which of the following is the most common cause of bloody discharge from nipple? </p><ol class=mt-3 type=A><li>Fibroadenomas</li><li>Fibrocystic breast disease</li><li>Lobular carcinoma in situ</li><li>Intraductal papilloma</li></ol><button aria-controls=explanation-XDV aria-expanded=false class="btn btn-secondary" data-target=#explanation-XDV data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-XDV><p class=correct-answer><strong>Answer:</strong> D</p><span style="text-decoration: underline;"><strong>Intraductal papilloma</strong></span><br><br><span style="text-decoration: underline;"><strong>Definition</strong></span><br>Wart-like benign Breast tissue growth within the Lactation ducts<br><span style="text-decoration: underline;"><strong><br>Epidemiology</strong></span><br>Peak Incidence: age 35-55 years old (mean age 48 years old)<br><span style="text-decoration: underline;"><strong><br>Pathophysiology</strong></span><br> 1. Mechanism of growth appears to be proliferative fibrocystic epithelial hyperplasia<br> 2. Broad-based or pedunculated polypoid epithelial growth of size 2-3 mm and within Lactation duct<br> 3. Localized within 1 cm of nipple in 90% of cases<br><span style="text-decoration: underline;"><strong><br></strong><strong>Symptoms</strong></span><br>1. Intermittent bloody discharge from one nipple is the classic presentation of intraductal papilloma. It is a benign tumor of major lactiferous ducts, that is most common in perimenopausal women. <br><strong>2. Most common cause of spontaneous, unilateral, bloody nipple discharge  </strong><br><br><span style="text-decoration: underline;"><strong>Diagnosis</strong></span>:<br><strong>Breast biopsy</strong>: Distinguishes Intraductal Papilloma from Breast Cancer as a cause of bloody Breast discharge</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>93. </span> A 33-year old women presented to the clinic with a 6-year history of bilateral breast pain, the pain get worse during her menses. Physical examination reveals multiple bilateral small breast masses. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Fibrocystic changes</li><li>Intraductal papilloma</li><li>Inflammatory breast carcinoma</li><li>Fibroadenoma</li></ol><button aria-controls=explanation-8VL aria-expanded=false class="btn btn-secondary" data-target=#explanation-8VL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-8VL><p class=correct-answer><strong>Answer:</strong> A</p><strong>Fibrocystic changes</strong> (previously, fibrocystic disease) is a catchall term that refers to mastalgia, breast cysts, and nondescript masses (usually in the upper outer part of the breast); these findings may occur in isolation or together. Breasts have a nodular and dense texture and are frequently tender when palpated. Fibrocystic changes cause the most commonly reported breast symptoms and have many causes. Fibrocystic changes are not associated with increased risk of cancer.<br><br><strong>Fibroadenomas</strong> are typically smooth, rounded, mobile, painless masses; they may be mistaken for cancer. They usually develop in women during their reproductive years and may decrease in size over time. Juvenile fibroadenoma, a variant, occurs in adolescents, and unlike fibroadenomas in older women, these fibroadenomas continue to grow over time. Simple fibroadenoma does not appear to increase risk of breast cancer; complex fibroadenoma may increase risk slightly.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>94. </span> Which of the following true regarding oral contraceptive? </p><ol class=mt-3 type=A><li>Increase the risk of thromboembolism</li><li>Increase the risk of endometrial carcinoma</li><li>Increase the risk of ectopic pregnancy</li><li>Increase the risk of ovarian carcinoma</li></ol><button aria-controls=explanation-YHS aria-expanded=false class="btn btn-secondary" data-target=#explanation-YHS data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-YHS><p class=correct-answer><strong>Answer:</strong> A</p><br> <table class="table table-responsive table-sm table-striped"> <tbody> <tr> <td><span style="text-decoration: underline;"><strong>Serious side effects of Oral contraceptive pills (OCPs)</strong></span></td> <td><span style="text-decoration: underline;"><strong>OCPs are protective against</strong></span></td> </tr> <tr> <td>Cardiovascular events/myocardial infarction</td> <td>Ovarian cysts and cancer</td> </tr> <tr> <td>Venous thromoboembolism</td> <td>Endometrial cancer</td> </tr> <tr> <td>Cerebrovascular events/stroke</td> <td>Benign breast disease</td> </tr> <tr> <td>Benign hepatic tumors</td> <td>Dysmenorrhea (anemia)</td> </tr> <tr> <td>Hypertension</td> <td> </td> </tr> </tbody> </table></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>95. </span> Which of the following used for emergency contraception? </p><ol class=mt-3 type=A><li>Levonorgestrel</li><li>Progestin Only Pill</li><li>Depot medroxyprogesterone acetate (DMPA)</li><li>Combined OCP</li></ol><button aria-controls=explanation-3J2 aria-expanded=false class="btn btn-secondary" data-target=#explanation-3J2 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-3J2><p class=correct-answer><strong>Answer:</strong> A</p>1. Emergency contraception (EC), are birth control measures that may be used after sexual intercourse to prevent pregnancy.<br>2. Usually, hormones (eg, ulipristal acetate, levonorgestrel) are used for emergency contraception (EC); they are taken as soon as possible within 120 h of unprotected intercourse.<br>3. Oral levonorgestrel (Plan B) is the most readily available emergency contraception; it works by delaying ovulation but is ineffective post-fertilization. Patients desiring emergency contraception should be provided oral levonorgestrel as soon as possible, as the efficacy decreases with time.<br>4. The probability of pregnancy is reduced by 85% after levonorgestrel EC, which has a pregnancy rate of 2 to 3%.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>96. </span> A 21-year old lactating mother comes to the doctor with left breast pain that started few days ago. The pain is associated with fever and fatigue. Examination shows tenderness, and swelling of the left breast. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Inflammatory breast carcinoma</li><li>Mastitis</li><li>Fat necrosis of the breast</li><li>Fibrocystic disease</li></ol><button aria-controls=explanation-RER aria-expanded=false class="btn btn-secondary" data-target=#explanation-RER data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-RER><p class=correct-answer><strong>Answer:</strong> B</p><strong>Breast infections (mastitis)</strong> cause pain, erythema, and swelling; an abscess can produce a discrete mass. Infections are extremely rare except during the puerperium (postpartum) or after penetrating trauma. They may occur after breast surgery. Puerperal mastitis, usually due to Staphylococcus aureus, can cause massive inflammation and severe breast pain, sometimes with an abscess. If infection occurs under other circumstances, an underlying cancer should be sought promptly.<br><br><strong>Inflammatory breast carcinoma </strong><br>It is an uncommon form of breast cancer. It presents as erythematous and edematous plaque with a “peau d’orange” appearance overlying a breast mass, commonly with axillary lymphadenopathy.<br><br><strong>Fibrocystic changes</strong> (previously, fibrocystic disease) is a catchall term that refers to mastalgia, breast cysts, and nondescript masses (usually in the upper outer part of the breast); these findings may occur in isolation or together. Breasts have a nodular and dense texture and are frequently tender when palpated. Fibrocystic changes cause the most commonly reported breast symptoms and have many causes. Fibrocystic changes are not associated with increased risk of cancer.<br><br><strong>Fat necrosis of the breast</strong> is associated with breast trauma or surgery (e.g. reduction mammoplasty). <br>Fat necrosis can mimic breast cancer in its clinical and radiographic features as fixed mass, skin or  nipple retraction, evidence of calcification on mammography and appears solid (hypoechoic mass) on  ultrasonography. <br>Breast malignancy has micro-calcification, while fat necrosis has coarse calcification. <br>Excisional, core or fine needle biopsy is diagnostic and shows fat globules and foamy histocytes. <br>No treatment is indicated, as it is self-limited condition.  <br><br><br><br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>97. </span> What is the mean age of menopause in normal women ? </p><ol class=mt-3 type=A><li>46</li><li>60</li><li>51</li><li>49</li></ol><button aria-controls=explanation-ZB2 aria-expanded=false class="btn btn-secondary" data-target=#explanation-ZB2 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ZB2><p class=correct-answer><strong>Answer:</strong> C</p>1. Menopause is physiologic or iatrogenic cessation of menses (amenorrhea) due to decreased ovarian function. <br>2. The mean age of menopause in normal women ranges between 50 and 52 years.<br>3. Changes in the menstrual cycle usually begin during a woman’s 40s, with variation in cycle length. A persistent difference in consecutive menstrual cycle length of ≥ 7 days defines early menopausal transition. Skipping ≥ 2 cycles defines late menopausal transition.<br><br>4. The marked fluctuations in estrogen levels may contribute to other peri-menopausal symptoms and signs such as (Breast tenderness, changes in menstrual flow, moodiness and exacerbation of menstrual migraines)<br>5. Symptoms can last from 6 mo to &gt; 10 yr and range from nonexistent to severe.<br>6. Manifestations may include hot flushes and vulvovaginal atrophy.<br>7. Diagnosis is clinical: absence of menses for 1 year. <br>8. Manifestations may be treated (eg, with lifestyle modification, complementary and alternative medicine, and/or hormone therapy).</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>98. </span> Which of the following correlates most with cervical dysplasia? </p><ol class=mt-3 type=A><li>HPV 6 and 11</li><li>HPV 16 and 18</li><li>HPV 31 and 33</li><li>HPV 33 and 35</li></ol><button aria-controls=explanation-IUC aria-expanded=false class="btn btn-secondary" data-target=#explanation-IUC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-IUC><p class=correct-answer><strong>Answer:</strong> B</p>1. <strong>Cervical cancer</strong> is caused by persistent infection with human papillomavirus (HPV) and accounts for one in ten cancers diagnosed in women worldwide. It is usually a squamous carcinoma.<br>2. Persistence of HPV infection is the most important factor in developing cervical cancer; HPV is detected in 99% of cervical tumours.<br>3. There are around 80 types of HPV that are related to cervical cancer.<br>4. The <span style="text-decoration: underline;"><strong>high-risk types</strong></span> - HPV 16 and 18 - are highly involved in 70% of cervical cancer<br>5. Subtypes 6 and 11 typically have a low malignant potential. The subtypes 31, 33, and 35 have an intermediate potential for dysplasia.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>99. </span> Which of the following medications is <span style="text-decoration: underline;"><strong>not</strong></span> contraindicated during pregnancy? </p><ol class=mt-3 type=A><li>Isotretinoin</li><li>Inhaled steroids</li><li>Streptomycin</li><li>Lithium</li></ol><button aria-controls=explanation-TI9 aria-expanded=false class="btn btn-secondary" data-target=#explanation-TI9 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-TI9><p class=correct-answer><strong>Answer:</strong> B</p>1. <strong>Inhaled steroids</strong> can be used during pregnancy. <br>2. <strong>Lithium</strong> is associated with Ebstein’s anomaly and other cardiac diseases. <br>3. <strong>Isotretinoin</strong> is associated with heart and great vessel defects, craniofacial dysmorphism and deafness. <br>4. <strong>Streptomycin</strong> is associated with CN VIII damage/ototoxicity. <br> <br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>100. </span> Which of the following is an absolute contraindication for oral contraceptive ? </p><ol class=mt-3 type=A><li>Hyperlipidemia</li><li>Diabetes Mellitus</li><li>Active Liver disease</li><li>Migraine</li></ol><button aria-controls=explanation-2V8 aria-expanded=false class="btn btn-secondary" data-target=#explanation-2V8 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-2V8><p class=correct-answer><strong>Answer:</strong> C</p><strong>Absolute Contraindications</strong><br><br>1. Migraine Headache with aura<br>2. Breast Cancer ( Hormone Dependent Cancer ) <br>3. Venous Thrombosis history or risk<br>4. Vascular disease e.g CAD , CVA<br>5. Pregnancy<br>6. Active Liver disease e.g Viral Hepatitis , Cirrhosis <br>7. Undiagnosed Vaginal Bleeding<br>8. Tobacco Use (Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use.)<br>9. Thrombophilia<br>10. Uncontrolled Hypertension ( SBP &gt; 160 , DBP &gt; 99 ) <br>11. Diabetes Mellitus with vascular complication<br><br><strong>Relative Contraindications</strong><br>1. Lactation (first 6 weeks to 6 months) : Increased Hypercoagulability in the postpartum period<br>2. Long leg cast or other prolonged immobility <br>3. Hyperlipidemia<br>4. Postpartum &lt; 3 weeks : Hypercoagulable state <br>5. Migraine<br>6. Diabetes Mellitus<br>7. Controlled Hypertension</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>101. </span> Which of the following is the earliest sign of magnesium sulfate toxicity? </p><ol class=mt-3 type=A><li>Confusion</li><li>Hypotension</li><li>Weakness</li><li>Depression of the deep tendon reflexes</li></ol><button aria-controls=explanation-STN aria-expanded=false class="btn btn-secondary" data-target=#explanation-STN data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-STN><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Magnesium sulfate</strong> is given to women with eclampsia and severe preeclampsia in order to prevent the further development of seizures while delivery of the fetus accomplished. <br>2. <strong>Depressed deep tendon reflexes</strong> is the earliest sign of magnesium sulfate toxicity which requires stopping of the magnesium sulfate infusion and administration of calcium gluconate. <br>3. Delivery is the most important overall treatment of eclampsia.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>102. </span> A 30-year-old woman comes to the doctor with severe pain during sexual intercourse. She also complains of dysmenorrhea, and pain with defecation. She and her husband have had frequent unprotected sexual intercourse for over a year. Which of the following is the treatement of choice for this patient? </p><ol class=mt-3 type=A><li>Urethropexy</li><li>IV estrogen</li><li>Pelvic muscle exercises</li><li>Oral contraceptive</li></ol><button aria-controls=explanation-2XJ aria-expanded=false class="btn btn-secondary" data-target=#explanation-2XJ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-2XJ><p class=correct-answer><strong>Answer:</strong> D</p>1. <strong>Endometriosis</strong> is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity<br>2. Can be found anywhere; most common sites are ovary (frequently bilateral), pelvis, peritoneum. In ovary, appears as endometrioma (blood-flled “chocolate cyst”). <br>3. Characterized by cyclic pelvic pain, bleeding, dysmenorrhea, dyspareunia, dyschezia (pain with defecation), infertility; normal-sized uterus. <br>4. Laparoscopy is the gold standard for the diagnosis of endometriosis. <br>5. Treatment: NSAIDs, OCPs, progestins, GnRH agonists, danazol, laparoscopic removal.<br>6. Oral contraceptive pills are first line agents in the treatment of endometriosis in young women desiring future fertility.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>103. </span> Which of the following is associated with an increased risk of endometrial cancer? </p><ol class=mt-3 type=A><li>Age &lt;40</li><li>Hyperlipidemia</li><li>Obesity</li><li>Smoking</li></ol><button aria-controls=explanation-F7K aria-expanded=false class="btn btn-secondary" data-target=#explanation-F7K data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-F7K><p class=correct-answer><strong>Answer:</strong> C</p>1. <strong>Endometrial cancer</strong> is usually endometrioid adenocarcinoma.<br>2. Typically, postmenopausal vaginal bleeding occurs.<br>3. Approximately 75% of women with endometrial cancer are postmenopausal. Thus, the most common symptom is postmenopausal bleeding.<br>4. Endometrial cancer is more common in developed countries where the diet is high in fat. <br>5. Diagnosis is by biopsy. <br>6. Staging is surgical. (Stage endometrial cancer surgically via laparotomy, laparoscopy, or a robotic-assisted surgery.)<br>7. Treatment requires hysterectomy, bilateral salpingo-oophorectomy, and, in high-risk patients, usually pelvic and para-aortic lymphadenectomy. <br>8. For advanced cancer, radiation, hormone, or cytotoxic therapy is usually indicated.<br><br><strong>Major risk factors for endometrial cancer are:</strong><br>1. Unopposed estrogen<br>2. Age &gt; 50<br>3. Obesity<br>4. Diabetes<br><br><strong>Other risk factors include</strong><br>1. Tamoxifen use for &gt; 5 yr<br>2. Previous pelvic radiation therapy<br>3. A personal or family history of breast or ovarian cancer<br>4. Family history of hereditary nonpolyposis colorectal cancer or possibly, among 1st-degree relatives, endometrial cancer<br>5. Hypertension</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>104. </span> Which of the following is the most common cause of unilateral nonbloody nipple discharge? </p><ol class=mt-3 type=A><li>Invasive lobular carcinoma</li><li>Ductal carcinoma in situ</li><li>Intraductal papilloma</li><li>Fibroadenoma</li></ol><button aria-controls=explanation-0OE aria-expanded=false class="btn btn-secondary" data-target=#explanation-0OE data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-0OE><p class=correct-answer><strong>Answer:</strong> C</p><span style="text-decoration: underline;"><strong>Intraductal papilloma </strong></span><br><br>1. Benign lesions of ductal tissue that may have malignant potential <br>2. <span style="text-decoration: underline;"><strong>Presents</strong></span> with􏰄 bloody or nonbloody discharge from nipple on stimulation, breast pain; palpable mass behind areola <br>3. <strong>The most common cause of unilateral non-bloody nipple discharge is intraductal papilloma.</strong><br>4. <span style="text-decoration: underline;"><strong>Diagnosis</strong></span> :excisional biopsy used to rule out cancer; ductal lavage by microcatheter can be used to test for abnormal intraductal cells and is more accurate than examination of aspirated nipple fluid.<br>5. <span style="text-decoration: underline;"><strong>Treatment</strong></span> :surgical excision</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>105. </span> A patient with endometriosis at greatest risk of developing which of the following?<br><br> </p><ol class=mt-3 type=A><li>Breast cancer</li><li>Premature rupture of the membranes</li><li>Endometrial cancer</li><li>Infertility</li></ol><button aria-controls=explanation-MYX aria-expanded=false class="btn btn-secondary" data-target=#explanation-MYX data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-MYX><p class=correct-answer><strong>Answer:</strong> D</p>1. Endometriosis is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity.<br>2. Patients with endometriosis do not frequently have any physical examination findings beyond tenderness related to the site of involvement.<br>3. The most common finding is nonspecific pelvic tenderness.<br>4. Most commonly affects women age 25-35 with nulliparity or early menarche <br><br><span style="text-decoration: underline;">Risk factors </span><br>1. Nulliparity <br>2. Early menarche <br>3. Shorter menstrual cycles <br>4. Menstrual outflow obstruction  <br><br><span style="text-decoration: underline;">Clinical picture:</span><br>1. Dyspareunia <br>2. Dysmenorrhea <br>3. Pelvic pain <br>4. Infertility <br><br>Diagnosis: Laparoscopy is considered the primary diagnostic modality for endometriosis (gold standard).<br><br>Treatment:<br>1. First-line therapy: Continuous oral progesterone or oral contraceptive pill (OCP). Progesterone inhibits endometrial growth. <br>2. Second-line therapy: Testosterone derivatives (Danocrine or danazol) or GnRH analogs (Lupron or leuprolide)  <br>Complications of endometriosis may include or fall into the following 3 categories:<br>1. Infertility/subfertility <br>2. Chronic pelvic pain and subsequent disability <br>3. Anatomic disruption of involved organ systems (eg, adhesions, ruptured cysts)</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>106. </span> A 20-year old women presented to the clinic with a firm, painless mass in her left breast. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Fibrocystic disease</li><li>Fibroadenoma</li><li>Mastitis</li><li>Inflammatory breast carcinoma</li></ol><button aria-controls=explanation-WOT aria-expanded=false class="btn btn-secondary" data-target=#explanation-WOT data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-WOT><p class=correct-answer><strong>Answer:</strong> B</p><strong>Fibroadenomas</strong> are typically smooth, rounded, mobile, painless masses; they may be mistaken for cancer. They usually develop in women during their reproductive years and may decrease in size over time. Juvenile fibroadenoma, a variant, occurs in adolescents, and unlike fibroadenomas in older women, these fibroadenomas continue to grow over time. Simple fibroadenoma does not appear to increase risk of breast cancer; complex fibroadenoma may increase risk slightly. It is the most common breast lesion in women &lt; 30 years of age.<br><br><strong>Fibrocystic changes</strong> (previously, fibrocystic disease) is a catchall term that refers to mastalgia, breast cysts, and nondescript masses (usually in the upper outer part of the breast); these findings may occur in isolation or together. Breasts have a nodular and dense texture and are frequently tender when palpated. Fibrocystic changes cause the most commonly reported breast symptoms and have many causes. Fibrocystic changes are not associated with increased risk of cancer.<br><br><strong>Breast infections (mastitis) </strong>cause pain, erythema, and swelling; an abscess can produce a discrete mass. Infections are extremely rare except during the puerperium (postpartum) or after penetrating trauma. They may occur after breast surgery. Puerperal mastitis, usually due to Staphylococcus aureus, can cause massive inflammation and severe breast pain, sometimes with an abscess. If infection occurs under other circumstances, an underlying cancer should be sought promptly.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>107. </span> A 35-year-old woman at 32 weeks gestation is brought to the emergency room with sudden onset of heavy vaginal bleeding. She has no pain or uterine contractions. Examination shows an active bright red bleeding from the cervix. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Vasa previa</li><li>Placenta previa</li><li>Threatened abortion</li><li>Incomplete abortion</li></ol><button aria-controls=explanation-DQA aria-expanded=false class="btn btn-secondary" data-target=#explanation-DQA data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-DQA><p class=correct-answer><strong>Answer:</strong> B</p><span style="text-decoration: underline;"><strong>Placenta Previa <br></strong></span><br>1. <span style="text-decoration: underline;"><strong>Definition</strong></span>: A placenta that is situated in the lower uterine segment. <br>2. <span style="text-decoration: underline;"><strong>Risk factors</strong></span>: Prior C-sections, grand multiparous, advanced maternal age, multiple gestation, prior placenta previa. <br>3. <span style="text-decoration: underline;"><strong>Symptoms</strong></span>: Painless, third trimester, bright red bleeding that often ceases in 1–2 hours with or without uterine contractions.  <br><span style="text-decoration: underline;"><strong><br>On Examination</strong></span>: <br>1. Fundal level and uterine external palpation are normal. <br>2. Pelvic examination is absolutely contraindicated (Fatal bleeding).  <br><span style="text-decoration: underline;"><strong><br>Diagnosis</strong></span>: Transabdominal (Not transvaginal) ultrasound. (Do not perform a vaginal exam)<br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span>: <br>1. Management of placenta previa depends on the severity of bleeding and the age of pregnancy. <br>2. Resuscitation is the best next step.<br>3. Bed rest and sexual abstinence. <br>4.Tocolytics can be used to delay delivery and reduce maternal bleeding risk in cases of a preterm fetus with immature lungs and mild maternal bleeding. <br>5.When delivery is indicated, perform by caesarean section.<br>6.Vaginal delivery can be performed with a low-lying placenta.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>108. </span> Which of the following viruses is associated with cervical cancer? </p><ol class=mt-3 type=A><li>Human papillomavirus</li><li>Herpes simplex viruses type 2</li><li>Cytomegalovirus</li><li>Herpes simplex viruses type 6</li></ol><button aria-controls=explanation-AO1 aria-expanded=false class="btn btn-secondary" data-target=#explanation-AO1 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-AO1><p class=correct-answer><strong>Answer:</strong> A</p>1. Cervical cancer is usually a squamous cell carcinoma caused by human papillomavirus infection.<br>2. 80 to 85% of all cervical cancers are squamous cell carcinoma; most of the rest are adenocarcinomas. <br>3. Risk factors for cervical cancer include the following: Multiparity, smoking, early initiation of intercourse, multiple sexual partners, HIV infection, venereal warts, family history and HPV: Types 6 and 11.<br>4. Cervical neoplasia is asymptomatic; the first symptom of early cervical cancer is usually irregular, often postcoital vaginal bleeding.<br>5. May present with postcoital bleeding, menorrhagia, pelvic pain, or vaginal discharge. <br>6. Diagnosis is by a screening cervical Pap test and biopsy.<br>7. Treatment usually involves surgical resection for early-stage disease or radiation therapy plus chemotherapy for locally advanced disease.If the cancer has widely metastasized, chemotherapy is often used alone.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>109. </span> A 30-year-old woman comes to the doctor with severe pain during sexual intercourse. She also complains of dysmenorrhea, and pain with defecation. She and her husband have had frequent unprotected sexual intercourse for over a year.<br><br>Which of the following is the definitive test for diagnosing endometriosis? </p><ol class=mt-3 type=A><li>Laparoscopy</li><li>Ultrasound</li><li>Pap smear</li><li>Quantitative hCG testing</li></ol><button aria-controls=explanation-5KW aria-expanded=false class="btn btn-secondary" data-target=#explanation-5KW data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-5KW><p class=correct-answer><strong>Answer:</strong> A</p>1. <span style="text-decoration: underline;"><strong>Endometriosis</strong></span> is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity<br>2. Can be found anywhere; most common sites are ovary (frequently bilateral), pelvis, peritoneum. In ovary, appears as endometrioma (blood-flled “chocolate cyst”). <br>3. <strong>Characterized</strong> by cyclic pelvic pain, bleeding, dysmenorrhea, dyspareunia, dyschezia (pain with defecation), infertility; normal-sized uterus. <br>4. <strong>Laparoscopy is the gold standard</strong> for the diagnosis of endometriosis. <br>5. Treatment: NSAIDs, OCPs, progestins, GnRH agonists, danazol, laparoscopic removal.<br>6. Oral contraceptive pills are first line agents in the treatment of endometriosis in young women desiring future fertility.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>110. </span> Which of the following is the most accurate test for primary syphilis? </p><ol class=mt-3 type=A><li>VDRL</li><li>RPR</li><li>Dark field microscopy</li><li>Lymph node biopsy</li></ol><button aria-controls=explanation-HJQ aria-expanded=false class="btn btn-secondary" data-target=#explanation-HJQ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-HJQ><p class=correct-answer><strong>Answer:</strong> C</p><span style="text-decoration: underline;"><strong>Primary syphilis </strong></span><br>1. Disease caused by the spirochete <strong>Treponema pallidum</strong> (only transmitted by sexual contact or from mother to child) <br>2. <span style="text-decoration: underline;"><strong>Incubation period:</strong></span> 6 weeks.<br>3. <span style="text-decoration: underline;"><strong>Characterized</strong></span> by painless chancre and painless lymphadenopathy. <br>4. Chancre is a well demarcated ulcer with indurated base, and it resolves spontaneously without scar formation. <br>5. <strong>Dark field microscopy</strong>: best initial test.<br>6. VDRL and rapid plasma regain (RPR) are 80% sensitive screening tests.<br>7. Fluorescent treponemal antibody absorption (FTA-ABS) or microhemag-glutination assay for antibodies to treponemes (MHA-TP) used to confirm diagnosis<br>8. <span style="text-decoration: underline;"><strong>Treatment</strong></span>: Penicillin is the drug of choice for all patients</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>111. </span> Which of the following is the treatment of choice for stress incontinence? </p><ol class=mt-3 type=A><li>Propranolol</li><li>Pelvic muscle exercises</li><li>Alpha blockers</li><li>Oxybutynin</li></ol><button aria-controls=explanation-FUL aria-expanded=false class="btn btn-secondary" data-target=#explanation-FUL data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-FUL><p class=correct-answer><strong>Answer:</strong> B</p>1. Stress incontinence is a very common in middle-age women who have had many pregnancies and vaginal deliveries. They leak small amounts of urine whenever intra-abdominal pressure suddenly increases (e.g. coughing, sneezing, laughing or lifting a heavy object)<br>2. Pressure on the bladder with an enlarging uterus frequently results in an involuntary loss of urine.<br>3. Diagnosis is usually based on the history and physical examination showing evidence of pelvic floor weakness such as uterine prolapse and or cystocele. <br>4. Management is strengthening the pelvic diaphragm with Kegel exercises.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>112. </span> A 25 year old nulliparous women at 9 weeks comes to the doctor with symptoms of urinary tract infection. Regarding antibiotics which of the following is the most appropriate ? </p><ol class=mt-3 type=A><li>Amoxicillin</li><li>Doxycycline</li><li>Ciprofloxacin</li><li>Bactrim</li></ol><button aria-controls=explanation-7UC aria-expanded=false class="btn btn-secondary" data-target=#explanation-7UC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-7UC><p class=correct-answer><strong>Answer:</strong> A</p>Urinary tract infections (UTIs) are common in pregnancy.<br><br>UTIs are associated with risks to both the fetus and the mother, including pyelonephritis, preterm birth, low birth weight, and increased perinatal mortality.<br><br><span style="text-decoration: underline;">Pyelonephritis is the most common urinary tract complication in pregnant women,</span> occurring in approximately 2% of all pregnancies. <br><br>In most cases of bacteriuria and urinary tract infection (UTI) in pregnancy, the prognosis is excellent.<br><br><strong>Safe and Recommended </strong><br>1. Amoxicillin<br>2. Amoxicillin·clavulanate <br>3. Nitrofurantoin<br>4. Cephalexin<br><br><strong>Contraindicated</strong> <br>1. Fluoroquinolones e.g ciprofloxacin , levofloxacin<br>2. Tetracycline e.g Doxycycline<br>3. Trimethoprim-sulfamethoxazole e.g Bactrim</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>113. </span> A 35-year-old man presents to the physician with painless ulcer on the dorsal penis and bilateral regional lymphadenopathy. Which of the following is the most likely diagnosis? </p><ol class=mt-3 type=A><li>Tertiary syphilis</li><li>Latent syphilis</li><li>Secondary syphilis</li><li>Primary syphilis</li></ol><button aria-controls=explanation-D26 aria-expanded=false class="btn btn-secondary" data-target=#explanation-D26 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-D26><p class=correct-answer><strong>Answer:</strong> D</p>Syphilis<br><br>1. Syphilis occurs in primary, secondary, and tertiary stages (Infected people are contagious during the first 2 stages.)<br>2. Infection is usually transmitted by sexual contact (including genital, orogenital, and anogenital) but may be transmitted non-sexually by skin contact or transplacentally.<br>3. Syphilis may manifest at any stage and may affect multiple or single organs, mimicking many other disorders. <br>4. Syphilis may be accelerated by coexisting HIV infection; in these cases, eye involvement, meningitis, and other neurologic complications are more common and more severe.<br><br>Primary syphilis<br>1. After an incubation period of 3 to 4 wk (range 1 to 13 wk), a primary lesion (chancre) develops at the site of inoculation. <br>2. The initial red papule quickly forms a chancre, usually a painless ulcer with a firm base; when rubbed, it produces clear fluid containing numerous spirochetes. Nearby lymph nodes may be enlarged, firm, and non-tender.<br>3. The chancre usually heals in 3 to 12 weeks.<br>4. In primary stage of syphilis, serologic testing is not reliable and includes a high rate of false-negatives, so diagnosis is made via spirochete identification on dark field microscopy. <br>5. A single dose of intramuscular benzathine penicillin G is the treatment of choice for primary syphilis. In non-pregnant patients with penicillin allergy, a 2-week course of doxycycline can be used.<br><br><br> <table class="table table-responsive table-sm table-striped"> <tbody> <tr> <td><span style="text-decoration: underline;"><strong>Stage</strong></span></td> <td><span style="text-decoration: underline;"><strong>Clinical manifestations</strong></span></td> </tr> <tr> <td>Primary syphilis</td> <td>Painless genital ulcer (chancre)</td> </tr> <tr> <td>Secondary syphilis</td> <td>Lymphadenopathy, Condyloma lata and oral lesions</td> </tr> <tr> <td>Latent syphilis</td> <td>Asymptomatic</td> </tr> <tr> <td>Tertiary syphilis</td> <td>CNS and Cardiovascular involvement </td> </tr> </tbody> </table></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>114. </span> Which of the following is true regarding group B Streptococcus (GBS) Screening? </p><ol class=mt-3 type=A><li>Screening occurs at 16–18 weeks</li><li>Screening occurs at 5-10 weeks</li><li>Screening occurs at 25-30 weeks</li><li>Screening occurs at 35-37 weeks</li></ol><button aria-controls=explanation-ZS9 aria-expanded=false class="btn btn-secondary" data-target=#explanation-ZS9 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-ZS9><p class=correct-answer><strong>Answer:</strong> D</p>1. Bacterial infections can affect pregnant women from implantation of the fertilized ovum through the time of delivery and peripartum period. They may also affect the fetus and newborn. <br>2. <span style="text-decoration: underline;"><strong>Group B Streptococcus</strong></span> (GBS; Streptococcus agalactiae) is the most common cause of life-threatening infections in newborns and can also affect the mother.<br><br><strong><span style="text-decoration: underline;">CDC recommendations</span></strong><br>1. <strong>At 35-37 weeks’ gestation</strong>, all pregnant women should undergo screening with a vaginal and rectal swab for culture.<br>2. If the culture result is positive, the woman should be treated during labor <br><br><span style="text-decoration: underline;"><strong>Treatment</strong></span><br>1. During labor and until delivery, IV penicillin G or ampicillin <br>2. In penicillin-allergic patients at low risk for anaphylaxis, IV cefazolin; in those at high risk for anaphylaxis, IV clindamycin or erythromycin <br>3. The neonate must be carefully observed for signs and symptoms of disease</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>115. </span> Which of the following is used to follow the effectiveness of ovarian cancer treatment? </p><ol class=mt-3 type=A><li>Beta hCG</li><li>Alpha fetoprotein (AFP)</li><li>Cytokeratin</li><li>CA 125</li></ol><button aria-controls=explanation-6VC aria-expanded=false class="btn btn-secondary" data-target=#explanation-6VC data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-6VC><p class=correct-answer><strong>Answer:</strong> D</p>CA 125 is the only tumor marker recommended for clinical use in the diagnosis and management of ovarian cancer.<br><br>AFP is one of several tumor markers. Tumor markers are molecules in the blood that are higher when a person has certain cancers. AFP is found mainly in liver cancer and nonseminomatous germ cell tumors, which are rare.<br><br></div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>116. </span> Which of the following medications is used to induce ovulation? </p><ol class=mt-3 type=A><li>Spironolactone</li><li>Combined hormonal contraceptives</li><li>Clomiphene citrate</li><li>Eflornithine</li></ol><button aria-controls=explanation-VN4 aria-expanded=false class="btn btn-secondary" data-target=#explanation-VN4 data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-VN4><p class=correct-answer><strong>Answer:</strong> C</p>1. <span style="text-decoration: underline;"><strong>Clomiphene citrate</strong> </span>is used to induce ovulation in selected populations of anovulatory women, and in women with ovulatory infertility to increase follicular number and fertility.<br>2.<strong> First-line treatment</strong> for ovulation induction when fertility is desired is clomiphene citrate.<br>3. Metformin is indicated in polycystic ovarian syndrome patients with impaired glucose tolerance. It helps in preventing type 2 diabetes mellitus and correcting obesity, hirsutism, menstrual irregularity, and infertility.</div></div><div class="question-container mb-4 pt-4"><p class=question-text><span class=question-number>117. </span> A 71-year-old female present with vaginal dryness, burning and dyspareunia. She also has dysuria and increased urinary frequency. The symptoms have been present for several months but have intensified recently. Physical examination shows scarce pubic hair and reduced elasticity and turgor of the vulvar skin. Pale, dry and smooth vaginal epithelium is noted. Urine dipstick is normal. Which of the following is treatment of choice for this patient?<br><br><br> </p><ol class=mt-3 type=A><li>Bacterial Vaginosis</li><li>Candidiasis</li><li>Gonorrhoea</li><li>Atrophic vaginitis</li></ol><button aria-controls=explanation-YTZ aria-expanded=false class="btn btn-secondary" data-target=#explanation-YTZ data-toggle=collapse type=button><i class="fa fa-heart"></i> Explain</button><div class="collapse explanation-text rounded p-4 mt-3" id=explanation-YTZ><p class=correct-answer><strong>Answer:</strong> D</p><strong>Atrophic vaginitis</strong> is very common in postmenopausal women, due to the falling levels of estrogen. The term genitourinary syndrome of menopause (GSM) is now usually used instead of vulvovaginal atrophy or atrophic vaginitis.<br><br><span style="text-decoration: underline;">The following can lead to atrophic vaginitis occurring:</span><br>1. Natural menopause or oophorectomy.<br>2. Anti-estrogenic treatments - eg, tamoxifen, aromatase inhibitors.<br>3. Radiotherapy or chemotherapy.<br>4. It can also occur postpartum or with breast-feeding, due to reduced oestrogen levels.<br><br><strong>Symptoms</strong><br>1. There may be no symptoms.<br>2. Dryness of the vagina is the most common symptom.<br>3. There may be burning or itching of the vagina or vulva.<br>4. Dyspareunia.<br>5. Vaginal discharge (usually white or yellow).<br>6. Vaginal bleeding or postcoital bleeding.<br>7. Urinary symptoms - eg, increased frequency, nocturia, dysuria, recurrent UTI, stress incontinence or urgency.<br><br><strong>Signs</strong><br>1. External genitalia may show reduced pubic hair, reduced turgor or elasticity, and a narrow introitus.<br>2. Be aware that vaginal examination may be uncomfortable or painful if the patient has atrophic vaginitis.<br>3. Vaginal examination may show:<br>- Thin mucosa with diffuse erythema.<br>- Occasional petechiae or ecchymoses.<br>- Dryness.<br>- Lack of vaginal folds.</div></div></div> </div> </div> </div> <script crossorigin=anonymous integrity=sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN src=https://code.jquery.com/jquery-3.2.1.slim.min.js></script> <script crossorigin=anonymous integrity=sha384-vFJXuSJphROIrBnz7yo7oB41mKfc8JzQZiCq4NCceLEaO4IHwicKwpJf9c9IpFgh src=https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.3/umd/popper.min.js></script> <script crossorigin=anonymous integrity=sha384-alpBpkh1PFOepccYVYDB4do5UnbKysX5WZXm3XxPqe5iKTfUKjNkCk9SaVuEZflJ src=https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0-beta.2/js/bootstrap.min.js></script> <script crossorigin=anonymous integrity=sha384-pEQEqworOLIVB/Sf2Wwa1hyQ6OJEOnY0/IIIJDVJeAeURcs135rPsK+WdkVFJ0SF src=https://cdnjs.cloudflare.com/ajax/libs/anchor-js/4.1.0/anchor.min.js></script> <script id=inline>anchors.add('.question-text');</script> </body></html>